<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35445737</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-2423</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of oncology</Title>
          <ISOAbbreviation>Int J Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">69</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2022.5359</ELocationID>
        <Abstract>
          <AbstractText>Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is associated with a poor clinical prognosis. Despite the progress in the understanding of the molecular and genetic changes that promote tumorigenesis, effective treatment options are limited. The present review intended to identify and summarize major signaling pathways and genetic abnormalities involved in the pathogenesis of GBM, as well as therapies that target these pathways. Glioblastoma remains a difficult to treat tumor; however, in the last two decades, significant improvements in the understanding of GBM biology have enabled advances in available therapeutics. Significant genomic events and signaling pathway disruptions (NF‑κB, Wnt, PI3K/AKT/mTOR) involved in the formation of GBM were discussed. Current therapeutic options may only marginally prolong survival and the current standard of therapy cures only a small fraction of patients. As a result, there is an unmet requirement for further study into the processes of glioblastoma pathogenesis and the discovery of novel therapeutic targets in novel signaling pathways implicated in the evolution of glioblastoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Khabibov</LastName>
            <ForeName>Marsel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, I. M. Sechenov First Moscow State Medical University, 119992 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Garifullin</LastName>
            <ForeName>Airat</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology, Bashkir State Medical University, 450000 Ufa, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Boumber</LastName>
            <ForeName>Yanis</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology at The Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Khaddour</LastName>
            <ForeName>Karam</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernandez</LastName>
            <ForeName>Manuel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Khamitov</LastName>
            <ForeName>Firat</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology, Bashkir State Medical University, 450000 Ufa, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khalikova</LastName>
            <ForeName>Larisa</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology, Bashkir State Medical University, 450000 Ufa, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuznetsova</LastName>
            <ForeName>Natalia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuro‑Oncology, National Medical Research Center for Oncology, 344037 Rostov‑on‑Don, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kit</LastName>
            <ForeName>Oleg</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Abdominal Oncology Department, National Medical Research Center for Oncology, 344037 Rostov‑on‑Don, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kharin</LastName>
            <ForeName>Leonid</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Abdominal Oncology Department, National Medical Research Center for Oncology, 344037 Rostov‑on‑Don, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA060553</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA218802</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Oncol</MedlineTA>
        <NlmUniqueID>9306042</NlmUniqueID>
        <ISSNLinking>1019-6439</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">glioblastoma</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">mutations</Keyword>
        <Keyword MajorTopicYN="Y">signaling pathways</Keyword>
        <Keyword MajorTopicYN="Y">targeted therapy</Keyword>
        <Keyword MajorTopicYN="Y">tumor treating fields</Keyword>
      </KeywordList>
      <CoiStatement>YB has been a speaker for Amgen and Regeneron and has been an Advisor/Board Member for Alphageneron, G1 Therapeutics and Jazz Pharmaceuticals. The remaining authors have no competing interests to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>8</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35445737</ArticleId>
        <ArticleId IdType="pmc">PMC9084550</ArticleId>
        <ArticleId IdType="doi">10.3892/ijo.2022.5359</ArticleId>
        <ArticleId IdType="pii">69</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L. Epidemiology for primary brain tumors: A nationwide population-based study. J Neurooncol. 2017;131:525–546. doi: 10.1007/s11060-016-2318-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-016-2318-3</ArticleId>
            <ArticleId IdType="pubmed">27853959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13. doi: 10.1016/j.jocn.2018.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2018.05.002</ArticleId>
            <ArticleId IdType="pubmed">29801989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faleh TA, Juweid M. Epidemiology and outcome of glioblastoma. Exon Publications. 2017:143–153.</Citation>
        </Reference>
        <Reference>
          <Citation>Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al.  The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noab106</ArticleId>
            <ArticleId IdType="pmc">PMC8328013</ArticleId>
            <ArticleId IdType="pubmed">34185076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization  . Histological classification of tumors of the central nervous system. Lyon, France: IARC; 2016. </Citation>
        </Reference>
        <Reference>
          <Citation>Zong H, Parada LF, Baker SJ. Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol. 2015;7:a020610. doi: 10.1101/cshperspect.a020610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a020610</ArticleId>
            <ArticleId IdType="pmc">PMC4448618</ArticleId>
            <ArticleId IdType="pubmed">25635044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van Ginderachter JA. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife. 2020;9:e52176. doi: 10.7554/eLife.52176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.52176</ArticleId>
            <ArticleId IdType="pmc">PMC7000215</ArticleId>
            <ArticleId IdType="pubmed">32014107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaddour K, Johanns TM, Ansstas G. The landscape of novel therapeutics and challenges in glioblastoma multiforme: Contemporary state and future directions. Pharmaceuticals (Basel) 2020;13:389. doi: 10.3390/ph13110389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph13110389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa043330</ArticleId>
            <ArticleId IdType="pubmed">15758009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al.  Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2017.18718</ArticleId>
            <ArticleId IdType="pmc">PMC5820703</ArticleId>
            <ArticleId IdType="pubmed">29260225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, et al.  A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) Neuro Oncol. 2020;22:705–717. doi: 10.1093/neuonc/noz232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz232</ArticleId>
            <ArticleId IdType="pmc">PMC7229248</ArticleId>
            <ArticleId IdType="pubmed">31844890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, et al.  Central nervous system cancers, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1537–1570. doi: 10.6004/jnccn.2020.0052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2020.0052</ArticleId>
            <ArticleId IdType="pubmed">33152694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et al.  Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20:110–119. doi: 10.1016/S1470-2045(18)30675-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30675-2</ArticleId>
            <ArticleId IdType="pubmed">30522967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993. doi: 10.1016/j.ctrv.2020.101993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2020.101993</ArticleId>
            <ArticleId IdType="pubmed">32199197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(Suppl 5):v1–v100. doi: 10.1093/neuonc/noz150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz150</ArticleId>
            <ArticleId IdType="pmc">PMC6823730</ArticleId>
            <ArticleId IdType="pubmed">31675094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin VA, Leibel SA, Gutin PH.  Neoplasms of the central nervous system In: Cancer: Principles and Practice of Oncology. 6th edition. Lippincott Williams and Wilkins; Philadelphia, PA: 2001. pp. 2100–2160.</Citation>
        </Reference>
        <Reference>
          <Citation>Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.  Effects of radiotherapy with concomitant and adjuvant temozolo-mide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(09)70025-7</ArticleId>
            <ArticleId IdType="pubmed">19269895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18:3–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5563115</ArticleId>
            <ArticleId IdType="pubmed">28239999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amirian ES, Ostrom QT, Armstrong GN, Lai RK, Gu X, Jacobs DI, Jalali A, Claus EB, Barnholtz-Sloan JS, Il'yasova D, et al.  Aspirin, NSAIDs, and Glioma Risk: Original data from the glioma international Case-Control study and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2019;28:555–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6401283</ArticleId>
            <ArticleId IdType="pubmed">30482874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML. Long-term anti-inflam-matory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277–1281. doi: 10.1158/1055-9965.EPI-07-2621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1055-9965.EPI-07-2621</ArticleId>
            <ArticleId IdType="pmc">PMC6436627</ArticleId>
            <ArticleId IdType="pubmed">18483351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS, HCMV and Gliomas Symposium  Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012;14:246–255. doi: 10.1093/neuonc/nor227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nor227</ArticleId>
            <ArticleId IdType="pmc">PMC3280809</ArticleId>
            <ArticleId IdType="pubmed">22319219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369:985–986. doi: 10.1056/NEJMc1302145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1302145</ArticleId>
            <ArticleId IdType="pubmed">24004141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bei R, Marzocchella L, Turriziani M. The use of temozolo-mide for the treatment of malignant tumors: Clinical evidence and molecular mechanisms of action. Recent Pat Anticancer Drug Discov. 2010;5:172–187. doi: 10.2174/157489210791760526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/157489210791760526</ArticleId>
            <ArticleId IdType="pubmed">20594183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacal PM, D'Atri S, Orlando L, Bonmassar E, Graziani G. In vitro inactivation of human O6-alkylguanine DNA alkyl-transferase by antitumor triazene compounds. J Pharmacol Exp Ther. 1996;279:416–422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8859021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 1998;54:334–341. doi: 10.1124/mol.54.2.334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.54.2.334</ArticleId>
            <ArticleId IdType="pubmed">9687575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP. Depletion of O 6-alkylguanine-DNA alkyltrans-ferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 1993;67:1299–1302. doi: 10.1038/bjc.1993.241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1993.241</ArticleId>
            <ArticleId IdType="pmc">PMC1968485</ArticleId>
            <ArticleId IdType="pubmed">8512814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;17:105780. doi: 10.1016/j.phrs.2021.105780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2021.105780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017;19:1688–1697. doi: 10.1093/neuonc/nox092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nox092</ArticleId>
            <ArticleId IdType="pmc">PMC5716072</ArticleId>
            <ArticleId IdType="pubmed">28499022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–4740. doi: 10.1200/JCO.2008.19.8721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.19.8721</ArticleId>
            <ArticleId IdType="pubmed">19720927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28:334–340. doi: 10.1007/s12325-011-0007-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12325-011-0007-3</ArticleId>
            <ArticleId IdType="pubmed">21432029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, AldapeHoward Colman KD, Chakravarti A, Jeraj R, Armstrong TS, Scott Wefel J, et al.  RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM) J Clin Oncol. 2013;31:1. doi: 10.1200/jco.2013.31.15_suppl.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2013.31.15_suppl.1</ArticleId>
            <ArticleId IdType="pubmed">23129739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glio-blastoma. J Neurooncol. 2017;133:455–467. doi: 10.1007/s11060-017-2477-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-017-2477-x</ArticleId>
            <ArticleId IdType="pubmed">28527008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 Trial. Lancet Oncol. 2014;15:943–953. doi: 10.1016/S1470-2045(14)70314-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70314-6</ArticleId>
            <ArticleId IdType="pubmed">25035291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandsma D, van den Bent MJ. Pseudoprogression and pseu-doresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22:633–638. doi: 10.1097/WCO.0b013e328332363e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0b013e328332363e</ArticleId>
            <ArticleId IdType="pubmed">19770760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, et al.  Updated response assessment criteria for high-grade gliomas: Response assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28:1963–1972. doi: 10.1200/JCO.2009.26.3541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.26.3541</ArticleId>
            <ArticleId IdType="pubmed">20231676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31:3212. doi: 10.1200/JCO.2012.47.2464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.47.2464</ArticleId>
            <ArticleId IdType="pmc">PMC4021043</ArticleId>
            <ArticleId IdType="pubmed">23940216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, et al.  Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol. 2011;29:2689–2995. doi: 10.1200/JCO.2010.34.1636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.34.1636</ArticleId>
            <ArticleId IdType="pmc">PMC3139373</ArticleId>
            <ArticleId IdType="pubmed">21606416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, et al.  Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA. 2015;314:2535–2543. doi: 10.1001/jama.2015.16669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2015.16669</ArticleId>
            <ArticleId IdType="pubmed">26670971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, Gonzalez J, Palmer JD. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review. Cancers (Basel) 2019;11:174. doi: 10.3390/cancers11020174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11020174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M. Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncol. 2016;2:1460–1469. doi: 10.1001/jamaoncol.2016.1373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.1373</ArticleId>
            <ArticleId IdType="pmc">PMC6438173</ArticleId>
            <ArticleId IdType="pubmed">27310651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noorbakhsh A, Tang JA, Marcus LP, McCutcheon B, Gonda DD, Schallhorn CS, Talamini MA, Chang DC, Carter BS, Chen CC. Gross-total resection outcomes in an elderly population with glioblastoma: A SEER-based analysis. J Neurosurg. 2014;120:31–39. doi: 10.3171/2013.9.JNS13877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2013.9.JNS13877</ArticleId>
            <ArticleId IdType="pubmed">24205904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eigenbrod S, Trabold R, Brucker D, Erös C, Egensperger R, La Fougere C, Göbel W, Rühm A, Kretzschmar HA, Tonn JC, et al.  Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir (Wien) 2014;156:1427–1440. doi: 10.1007/s00701-014-2073-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-014-2073-1</ArticleId>
            <ArticleId IdType="pubmed">24792966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, Goetz C, Bink A, Pichlmeier U, ALA-Glioma Study Group  Counterbalancing risks and gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg. 2011;114:613–623. doi: 10.3171/2010.3.JNS097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2010.3.JNS097</ArticleId>
            <ArticleId IdType="pubmed">20397896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berntsen EM, Gulati S, Solheim O, Kvistad KA, Torp SH, Selbekk T, Unsgård G, Håberg AK. Functional magnetic resonance imaging and diffusion tensor tractography incorporated into an intraoperative 3-dimensional ultrasound-based neuronavigation system: Impact on therapeutic strategies, extent of resection, and clinical outcome. Neurosurgery. 2010;67:251–264. doi: 10.1227/01.NEU.0000371731.20246.AC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.NEU.0000371731.20246.AC</ArticleId>
            <ArticleId IdType="pubmed">20644410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, Weyerbrock A, Westermaier T, Senft C, Schucht P, et al.  Clinical benefit from resection of recurrent glioblastomas: Results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2016;18:96–104. doi: 10.1093/neuonc/nov145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov145</ArticleId>
            <ArticleId IdType="pmc">PMC4677413</ArticleId>
            <ArticleId IdType="pubmed">26243790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuccarini M, Giuliani P, Ziberi S, Carluccio M, Iorio PD, Caciagli F, Ciccarelli R. The role of Wnt signal in glioblastoma development and progression: A possible new pharmacological target for the therapy of this tumor. Genes (Basel) 2018;9:105. doi: 10.3390/genes9020105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes9020105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3–20. doi: 10.1002/1878-0261.12155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12155</ArticleId>
            <ArticleId IdType="pmc">PMC5748484</ArticleId>
            <ArticleId IdType="pubmed">29124875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao A, Brenneman B, Floyd D, Comeau L, Spurio K, Olmez I, Lee J, Nakano I, Godlewski J, Bronisz A, et al.  Statins affect human glioblastoma and other cancers through TGF-β inhibition. Oncotarget. 2019;10:1716–1728. doi: 10.18632/oncotarget.26733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.26733</ArticleId>
            <ArticleId IdType="pmc">PMC6422202</ArticleId>
            <ArticleId IdType="pubmed">30899443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108:3749–3754. doi: 10.1073/pnas.1014480108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1014480108</ArticleId>
            <ArticleId IdType="pmc">PMC3048093</ArticleId>
            <ArticleId IdType="pubmed">21321221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cyclin-dependent kinase inhibitor 2A. GeneCards. Weizmann institute of science;  Retrieved December 15, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Albensi BC. What is nuclear factor kappa B (NF-κB) doing in and to the mitochondrion? Front Cell Dev Biol. 2019;7:154. doi: 10.3389/fcell.2019.00154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00154</ArticleId>
            <ArticleId IdType="pmc">PMC6692429</ArticleId>
            <ArticleId IdType="pubmed">31448275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L, Tian Y, Liu L, Su M, Wang H, et al.  Role of the NFκB-signaling pathway in cancer. Onco Targets Ther. 2018;11:2063–2073. doi: 10.2147/OTT.S161109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S161109</ArticleId>
            <ArticleId IdType="pmc">PMC5905465</ArticleId>
            <ArticleId IdType="pubmed">29695914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2:823–830. doi: 10.1158/2326-6066.CIR-14-0112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0112</ArticleId>
            <ArticleId IdType="pmc">PMC4155602</ArticleId>
            <ArticleId IdType="pubmed">25187272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7:33440–33450. doi: 10.18632/oncotarget.7961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7961</ArticleId>
            <ArticleId IdType="pmc">PMC5078108</ArticleId>
            <ArticleId IdType="pubmed">26967052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget. 2010;1:530. doi: 10.18632/oncotarget.188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.188</ArticleId>
            <ArticleId IdType="pmc">PMC3248125</ArticleId>
            <ArticleId IdType="pubmed">21317449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crespo I, Vital AL, Gonzalez-Tablas M, Patino Mdel C, Otero A, Lopes MC, de Oliveira C, Domingues P, Orfao A, Tabernero MD. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol. 2015;185:1820–1833. doi: 10.1016/j.ajpath.2015.02.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2015.02.023</ArticleId>
            <ArticleId IdType="pubmed">25976245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balça-Silva J, Matias D, Carmo AD, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. Semin Cancer Biol. 2019;58:130–141. doi: 10.1016/j.semcancer.2018.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2018.09.007</ArticleId>
            <ArticleId IdType="pubmed">30266571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar SA, Dey G, Mukherjee A, Mandal M. Insights into molecular therapy of glioma: Current challenges and next generation blueprint. Acta Pharmacol Sin. 2017;38:591–613. doi: 10.1038/aps.2016.167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2016.167</ArticleId>
            <ArticleId IdType="pmc">PMC5457688</ArticleId>
            <ArticleId IdType="pubmed">28317871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas, Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. doi: 10.1038/nature07385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07385</ArticleId>
            <ArticleId IdType="pmc">PMC2671642</ArticleId>
            <ArticleId IdType="pubmed">18772890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials. Clin Cancer Res. 2019;25:1809–1816. doi: 10.1158/1078-0432.CCR-18-3181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3181</ArticleId>
            <ArticleId IdType="pmc">PMC8127866</ArticleId>
            <ArticleId IdType="pubmed">30514777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, Wang KY, Chang YH, Jiang T, Wang YZ. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Carcinogenesis. 2019;40:1229–1239. doi: 10.1093/carcin/bgz102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgz102</ArticleId>
            <ArticleId IdType="pubmed">31157866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, et al.  Glioblastoma with an oligodendroglioma component: Distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14:518–525. doi: 10.1093/neuonc/nor232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nor232</ArticleId>
            <ArticleId IdType="pmc">PMC3309852</ArticleId>
            <ArticleId IdType="pubmed">22326863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark KH, Villano JL, Nikiforova MN, Hamilton RL, Horbinski C. 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol. 2013;39:706–717. doi: 10.1111/nan.12031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12031</ArticleId>
            <ArticleId IdType="pmc">PMC4095883</ArticleId>
            <ArticleId IdType="pubmed">23363074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al.  Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–339. doi: 10.1038/nature12634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12634</ArticleId>
            <ArticleId IdType="pmc">PMC3927368</ArticleId>
            <ArticleId IdType="pubmed">24132290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brosh R, Rotter V. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 2009;9:701–713. doi: 10.1038/nrc2693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2693</ArticleId>
            <ArticleId IdType="pubmed">19693097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al.  Erratum: The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477. doi: 10.1016/j.cell.2013.09.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.09.034</ArticleId>
            <ArticleId IdType="pmc">PMC3910500</ArticleId>
            <ArticleId IdType="pubmed">24120142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F, Huang J, Liu X, Cheng Q, Luo C, Liu Z. CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell Int. 2020;20:7. doi: 10.1186/s12935-019-1085-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-019-1085-6</ArticleId>
            <ArticleId IdType="pmc">PMC6945521</ArticleId>
            <ArticleId IdType="pubmed">31911758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garofano L, Migliozzi S, Oh YT, D'Angelo F, Najac RD, Ko A, Frangaj B, Caruso FP, Yu K, Yuan J, et al.  Pathway-based clas-sification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021;2:141–156. doi: 10.1038/s43018-020-00159-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-020-00159-4</ArticleId>
            <ArticleId IdType="pmc">PMC7935068</ArticleId>
            <ArticleId IdType="pubmed">33681822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu VM, O'Connor KP, Shah AH, Eichberg DG, Luther EM, Komotar RJ, Ivan ME. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: A systematic review of the contemporary literature. J Neurooncol. 2020;148:221–229. doi: 10.1007/s11060-020-03528-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-020-03528-2</ArticleId>
            <ArticleId IdType="pubmed">32385699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>William D, Mokri P, Lamp N, Linnebacher M, Classen CF, Erbersdobler A, Schneider B. Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme. PLoS One. 2017;12:e0185208. doi: 10.1371/journal.pone.0185208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0185208</ArticleId>
            <ArticleId IdType="pmc">PMC5608330</ArticleId>
            <ArticleId IdType="pubmed">28934307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, et al.  Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: Prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017;23:6846–6855. doi: 10.1158/1078-0432.CCR-17-0890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-0890</ArticleId>
            <ArticleId IdType="pubmed">28855349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies. Oncogene. 2018;37:1561–1575. doi: 10.1038/s41388-017-0045-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-017-0045-7</ArticleId>
            <ArticleId IdType="pmc">PMC5860944</ArticleId>
            <ArticleId IdType="pubmed">29321659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu H, Zong H, Ma C, Ming X, Shang M, Li K, He X, Du H, Cao L. Epidermal growth factor receptor in glioblastoma. Oncol Lett. 2017;14:512–516. doi: 10.3892/ol.2017.6221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.6221</ArticleId>
            <ArticleId IdType="pmc">PMC5494611</ArticleId>
            <ArticleId IdType="pubmed">28693199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De S, Dermawan JK, Stark GR. EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci USA. 2014;111:11721–11726. doi: 10.1073/pnas.1412390111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1412390111</ArticleId>
            <ArticleId IdType="pmc">PMC4136585</ArticleId>
            <ArticleId IdType="pubmed">25071181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen PØ, Eskilsson E, et al.  EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013;125:683–698. doi: 10.1007/s00401-013-1101-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-013-1101-1</ArticleId>
            <ArticleId IdType="pmc">PMC3631314</ArticleId>
            <ArticleId IdType="pubmed">23429996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T, Koizumi F. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer. 2013;12:31. doi: 10.1186/1476-4598-12-31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-12-31</ArticleId>
            <ArticleId IdType="pmc">PMC3641008</ArticleId>
            <ArticleId IdType="pubmed">23617883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007;6:1167–1174. doi: 10.1158/1535-7163.MCT-06-0691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-06-0691</ArticleId>
            <ArticleId IdType="pubmed">17363510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cetintas VB, Batada NN. Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment? J Transl Med. 2020;18:45. doi: 10.1186/s12967-020-02219-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-020-02219-w</ArticleId>
            <ArticleId IdType="pmc">PMC6993356</ArticleId>
            <ArticleId IdType="pubmed">32000794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, et al.  A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010;12:95–103. doi: 10.1093/neuonc/nop015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nop015</ArticleId>
            <ArticleId IdType="pmc">PMC2940554</ArticleId>
            <ArticleId IdType="pubmed">20150372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024. doi: 10.1056/NEJMoa051918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa051918</ArticleId>
            <ArticleId IdType="pubmed">16282176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, et al.  RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phy. 2013;85:1206–1211. doi: 10.1016/j.ijrobp.2012.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2012.10.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, et al.  Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North central cancer treatment group study N0074. Int J Radiat Oncol Biol Phys. 2011;80:347–353. doi: 10.1016/j.ijrobp.2010.01.070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2010.01.070</ArticleId>
            <ArticleId IdType="pmc">PMC5753591</ArticleId>
            <ArticleId IdType="pubmed">20510539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010;24:1731–1745. doi: 10.1101/gad.1890510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1890510</ArticleId>
            <ArticleId IdType="pmc">PMC2922502</ArticleId>
            <ArticleId IdType="pubmed">20713517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L, Falini A, De Palma M, Bulfone A, Poliani PL, Galli R. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 2010;70:7500–7513. doi: 10.1158/0008-5472.CAN-10-2353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-2353</ArticleId>
            <ArticleId IdType="pubmed">20858720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, et al.  INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020;22:684–693. doi: 10.1093/neuonc/noz222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz222</ArticleId>
            <ArticleId IdType="pmc">PMC7229258</ArticleId>
            <ArticleId IdType="pubmed">31747009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1:a000034. doi: 10.1101/cshperspect.a000034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a000034</ArticleId>
            <ArticleId IdType="pmc">PMC2773619</ArticleId>
            <ArticleId IdType="pubmed">20066092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dresselhaus EC, Meffert MK. Cellular specificity of NF-κB function in the nervous system. Front Immunol. 2019;10:1043. doi: 10.3389/fimmu.2019.01043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01043</ArticleId>
            <ArticleId IdType="pmc">PMC6520659</ArticleId>
            <ArticleId IdType="pubmed">31143184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann-Morvinski D, Narasimamurthy R, Xia Y, Myskiw C, Soda Y, Verma IM. Targeting NF-κB in glioblastoma: A therapeutic approach. Sci Adv. 2016;2:e1501292. doi: 10.1126/sciadv.1501292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.1501292</ArticleId>
            <ArticleId IdType="pmc">PMC4730860</ArticleId>
            <ArticleId IdType="pubmed">26824076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest. 2004;84:941–951. doi: 10.1038/labinvest.3700123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.3700123</ArticleId>
            <ArticleId IdType="pubmed">15184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, et al.  EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell. 2012;48:771–784. doi: 10.1016/j.molcel.2012.09.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2012.09.028</ArticleId>
            <ArticleId IdType="pmc">PMC3526114</ArticleId>
            <ArticleId IdType="pubmed">23123196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap YS, McPherson JR, Ong CK, Rozen SG, The BT, Lee AS, Callen DF. The NF1 gene revisited-from bench to bedside. Oncotarget. 2014;5:5873–5892. doi: 10.18632/oncotarget.2194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2194</ArticleId>
            <ArticleId IdType="pmc">PMC4171599</ArticleId>
            <ArticleId IdType="pubmed">25026295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schäfer C, Göder A, Beyer M, Kiweler N, Mahendrarajah N, Rauch A, Nikolova T, Stojanovic N, Wieczorek M, Reich TR, et al.  Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells. Cell Signal. 2018;29:218–225. doi: 10.1016/j.cellsig.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2016.11.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanotto-Filho A, Braganhol E, Schröder R, de Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM, Moreira JC. NFκB inhibitors induce cell death in glioblastomas. Biochem Pharmacol. 2011;81:412–424. doi: 10.1016/j.bcp.2010.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2010.10.014</ArticleId>
            <ArticleId IdType="pubmed">21040711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinoda K, Kuboki S, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Miyazaki M. Pin1 facilitates NF-κ B activation and promotes tumour progression in human hepatocellular carcinoma. Br J Cancer. 2015;113:1323–1331. doi: 10.1038/bjc.2015.272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2015.272</ArticleId>
            <ArticleId IdType="pmc">PMC4815797</ArticleId>
            <ArticleId IdType="pubmed">26461058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros M, Candido MF, Valera ET, Brassesco MS. The multifaceted NF-kB: Are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors? Cell Mol Life Sci. 2021;78:6161–6200. doi: 10.1007/s00018-021-03906-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-021-03906-7</ArticleId>
            <ArticleId IdType="pubmed">34333711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phesse T, Flanagan D, Vincan E. Frizzled7: A promising Achilles' Heel for targeting the Wnt receptor complex to treat cancer. Cancers (Basel) 2016;8:50. doi: 10.3390/cancers8050050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers8050050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Liao Y, Qiu M, Shen W. Wnt/β-catenin signaling in neural stem cell homeostasis and neurological diseases. Neuroscientist. 2021;27:58–72. doi: 10.1177/1073858420914509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1073858420914509</ArticleId>
            <ArticleId IdType="pubmed">32242761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang C, Guo J, Chen H, Yao CJ, Zhuang DX, Wang Y, Tang WJ, Ren G, Yao Y, Wu JS, et al.  Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp Pathol. 2015;8:5327–5335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4503105</ArticleId>
            <ArticleId IdType="pubmed">26191234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yun EJ, Kim S, Hsieh JT, Baek ST. Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. Cell Death Dis. 2020;11:771. doi: 10.1038/s41419-020-02988-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-02988-8</ArticleId>
            <ArticleId IdType="pmc">PMC7498596</ArticleId>
            <ArticleId IdType="pubmed">32943609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tompa M, Kalovits F, Nagy A, Kalman B. Contribution of the Wnt pathway to defining biology of glioblastoma. Neuromolecular Med. 2018;20:437–451. doi: 10.1007/s12017-018-8514-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12017-018-8514-x</ArticleId>
            <ArticleId IdType="pubmed">30259273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori H, Yao Y, Learman BS, Kurozumi K, Ishida J, Ramakrishnan SK, Overmyer KA, Xue X, Cawthorn WP, Reid MA, et al.  Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion. Sci Rep. 2016;6:21520. doi: 10.1038/srep21520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep21520</ArticleId>
            <ArticleId IdType="pmc">PMC4748282</ArticleId>
            <ArticleId IdType="pubmed">26861754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rampazzo E, Persano L, Pistollato F, Moro E, Frasson C, Porazzi P, Della Puppa A, Bresolin S, Battilana G, Indraccolo S, et al.  Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis. 2013;4:e500. doi: 10.1038/cddis.2013.32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2013.32</ArticleId>
            <ArticleId IdType="pmc">PMC4098797</ArticleId>
            <ArticleId IdType="pubmed">23429286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Takada K, Di Z. Targeting Wnt/β-catenin pathway for drug therapy. Med Drug Discovery. 2020;8:100066. doi: 10.1016/j.medidd.2020.100066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.medidd.2020.100066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, et al.  Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020;184:53–62. doi: 10.1007/s10549-020-05817-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-020-05817-w</ArticleId>
            <ArticleId IdType="pmc">PMC7572714</ArticleId>
            <ArticleId IdType="pubmed">32803633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selivanova LS, Volganova KS, Abrosimov AY. Telomerase reverse transcriptase (TERT) promoter mutations in the tumors of human endocrine organs: Biological and prognostic value. Arkh Patol. 2016;78:62–69. doi: 10.17116/patol201678162-68. In Russian.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.17116/patol201678162-68</ArticleId>
            <ArticleId IdType="pubmed">27077147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017;133:1001–1016. doi: 10.1007/s00401-017-1690-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-017-1690-1</ArticleId>
            <ArticleId IdType="pmc">PMC5432658</ArticleId>
            <ArticleId IdType="pubmed">28255664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell RJ, Rube HT, Xavier-Magalhães A, Costa BM, Mancini A, Song JS, Costello JF. Understanding TERT promoter mutations: A common path to immortality. Mol Cancer Res. 2016;14:315–323. doi: 10.1158/1541-7786.MCR-16-0003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-16-0003</ArticleId>
            <ArticleId IdType="pmc">PMC4852159</ArticleId>
            <ArticleId IdType="pubmed">26941407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang JJ, Lin MC, Bai YX, Jing DD, Wong BC, Han SW, Lin J, Xu B, Huang CF, Kung HF. Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res. 2002;62:3226–3232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12036938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng SS, Gao Y, Chau DH, Li GH, Lai LH, Huang PT, Huang CF, Huang JJ, Chen YC, Kung HF, Lin MC. A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther. 2007;14:561–572. doi: 10.1038/sj.cgt.7701038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cgt.7701038</ArticleId>
            <ArticleId IdType="pubmed">17384579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavanya C, Sibin MK, Srinivas Bharath MM, Manoj MJ, Venkataswamy MM, Bhat DI, Narasinga Rao KV, Chetan GK. RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells. Cytotechnology. 2016;68:2311–2321. doi: 10.1007/s10616-016-0025-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10616-016-0025-8</ArticleId>
            <ArticleId IdType="pmc">PMC5101301</ArticleId>
            <ArticleId IdType="pubmed">27757712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Qian X, Wang B, Xia Y, Zheng Y, Du L, Xu D, Xing D, DePinho RA, Lu Z. Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nat Cell Biol. 2020;22:282–288. doi: 10.1038/s41556-020-0471-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-020-0471-6</ArticleId>
            <ArticleId IdType="pubmed">32066906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, et al.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012;3:954–987. doi: 10.18632/oncotarget.652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.652</ArticleId>
            <ArticleId IdType="pmc">PMC3660063</ArticleId>
            <ArticleId IdType="pubmed">23006971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development. Mol Cancer. 2017;16:100. doi: 10.1186/s12943-017-0670-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-017-0670-3</ArticleId>
            <ArticleId IdType="pmc">PMC5463420</ArticleId>
            <ArticleId IdType="pubmed">28592260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA. 2007;104:5569–5574. doi: 10.1073/pnas.0701005104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0701005104</ArticleId>
            <ArticleId IdType="pmc">PMC1838453</ArticleId>
            <ArticleId IdType="pubmed">17376864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, Cwiek P, Salm F, Leni Z, Shepherd PR, et al.  Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One. 2014;9:e94132. doi: 10.1371/journal.pone.0094132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0094132</ArticleId>
            <ArticleId IdType="pmc">PMC3981776</ArticleId>
            <ArticleId IdType="pubmed">24718026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L. PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol. 2011;104:155–167. doi: 10.1007/s11060-010-0492-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-010-0492-2</ArticleId>
            <ArticleId IdType="pubmed">21188471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA. 2005;102:1649–1654. doi: 10.1073/pnas.0406789102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0406789102</ArticleId>
            <ArticleId IdType="pmc">PMC545492</ArticleId>
            <ArticleId IdType="pubmed">15668399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baretić D, Williams RL. PIKKs-the solenoid nest where partners and kinases meet. Curr Opin Struct Biol. 2014;29:134–142. doi: 10.1016/j.sbi.2014.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sbi.2014.11.003</ArticleId>
            <ArticleId IdType="pubmed">25460276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302. doi: 10.1016/j.cub.2004.06.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2004.06.054</ArticleId>
            <ArticleId IdType="pubmed">15268862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013;23:53–62. doi: 10.1016/j.gde.2012.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gde.2012.12.005</ArticleId>
            <ArticleId IdType="pubmed">23317514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawlor MA, Alessi DR. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114:2903–2910. doi: 10.1242/jcs.114.16.2903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.114.16.2903</ArticleId>
            <ArticleId IdType="pubmed">11686294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, et al.  The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013;19:5722–5732. doi: 10.1158/1078-0432.CCR-13-0527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0527</ArticleId>
            <ArticleId IdType="pmc">PMC3815450</ArticleId>
            <ArticleId IdType="pubmed">24030701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007;67:11712–11720. doi: 10.1158/0008-5472.CAN-07-2223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2223</ArticleId>
            <ArticleId IdType="pubmed">18089801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agliano A, Balarajah G, Ciobota DM, Sidhu J, Clarke PA, Jones C, Workman P, Leach MO, Al-Saffar NMS. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy. Oncotarget. 2017;8:47969–47983. doi: 10.18632/oncotarget.18206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.18206</ArticleId>
            <ArticleId IdType="pmc">PMC5564619</ArticleId>
            <ArticleId IdType="pubmed">28624789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Michael Yu HH, Stieber VW, Malone SC, et al.  A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblas-toma: Results of NRG Oncology RTOG 0913. Neuro Oncol. 2018;20:666–673. doi: 10.1093/neuonc/nox209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nox209</ArticleId>
            <ArticleId IdType="pmc">PMC5892159</ArticleId>
            <ArticleId IdType="pubmed">29126203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: A perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012;69:849–860. doi: 10.1007/s00280-011-1773-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-011-1773-y</ArticleId>
            <ArticleId IdType="pubmed">22037923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, et al.  Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082) Clin Cancer Res. 2016;22:4797–4806. doi: 10.1158/1078-0432.CCR-15-3153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-3153</ArticleId>
            <ArticleId IdType="pubmed">27143690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S National Library of Medincine (NIH)  NCT Neuro Master Match-N2M2 (NOA-20)   ClinicalTrials.gov Identifier: NCT03158389.  https://clinicaltrials.gov/ct2/show/NCT03158389. Accessed May 18, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, et al.  Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016;534:272–276. doi: 10.1038/nature17963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature17963</ArticleId>
            <ArticleId IdType="pmc">PMC4902179</ArticleId>
            <ArticleId IdType="pubmed">27279227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babak S, Mason WP. mTOR inhibition in glioblastoma: Requiem for a dream? Neuro Oncol. 2018;20:584–585. doi: 10.1093/neuonc/noy034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy034</ArticleId>
            <ArticleId IdType="pmc">PMC5892149</ArticleId>
            <ArticleId IdType="pubmed">29608764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, et al.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:75. doi: 10.1186/s12943-018-0796-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-018-0796-y</ArticleId>
            <ArticleId IdType="pmc">PMC5861621</ArticleId>
            <ArticleId IdType="pubmed">29558960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvalho B, Lopes JM, Silva R, Peixoto J, Leitão D, Soares P, Fernandes AC, Linhares P, Vaz R, Lima J. The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. Sci Rep. 2021;11:6067. doi: 10.1038/s41598-021-85385-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-85385-1</ArticleId>
            <ArticleId IdType="pmc">PMC7966794</ArticleId>
            <ArticleId IdType="pubmed">33727583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarty JH. Glioblastoma resistance to anti-VEGF therapy: Has the challenge been MET? Clin Cancer Res. 2013;19:1631–1633. doi: 10.1158/1078-0432.CCR-13-0051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0051</ArticleId>
            <ArticleId IdType="pmc">PMC3618531</ArticleId>
            <ArticleId IdType="pubmed">23403631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab. Clin Transl Oncol. 2019;21:1413–1423. doi: 10.1007/s12094-019-02070-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-019-02070-6</ArticleId>
            <ArticleId IdType="pubmed">30877636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, et al.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA. 2013;110:E2987–E2996. doi: 10.1073/pnas.1302725110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1302725110</ArticleId>
            <ArticleId IdType="pmc">PMC3740879</ArticleId>
            <ArticleId IdType="pubmed">23882082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, et al.  Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: Efficacy, safety, and hepatocyte growth factor and O6-methylguanine-DNA methyltransferase biomarker analyses. J Clin Oncol. 2017;35:343–351. doi: 10.1200/JCO.2015.64.7685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.64.7685</ArticleId>
            <ArticleId IdType="pubmed">27918718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia MM, Gil MJ, Losada E, Martin Soberón MC, Mesia Barroso C, Foro P, Capellades J, Sarmiento B, Bruna J, Verger E, et al.  GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB. Ann Oncol. 2019;30:v147. doi: 10.1093/annonc/mdz243.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz243.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillemot F, Zimmer C. From cradle to grave: The multiple roles of fibroblast growth factors in neural development. Neuron. 2011;71:574–588. doi: 10.1016/j.neuron.2011.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2011.08.002</ArticleId>
            <ArticleId IdType="pubmed">21867876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frinchi M, Bonomo A, Trovato-Salinaro A, Condorelli DF, Fuxe K, Spampinato MG, Mudò G. Fibroblast growth factor-2 and its receptor expression in proliferating precursor cells of the subventricular zone in the adult rat brain. Neurosci Lett. 2008;447:20–25. doi: 10.1016/j.neulet.2008.09.059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2008.09.059</ArticleId>
            <ArticleId IdType="pubmed">18835325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–563. doi: 10.1093/annonc/mdt419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdt419</ArticleId>
            <ArticleId IdType="pmc">PMC4433501</ArticleId>
            <ArticleId IdType="pubmed">24265351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al.  COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777–D783. doi: 10.1093/nar/gkw1121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkw1121</ArticleId>
            <ArticleId IdType="pmc">PMC5210583</ArticleId>
            <ArticleId IdType="pubmed">27899578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, et al.  Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma. Cancer Discov. 2019;9:1686–1695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31575540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, et al.  First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9:1696–1707. doi: 10.1158/2159-8290.CD-19-0555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0555</ArticleId>
            <ArticleId IdType="pubmed">31575541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554) Int J Pharm. 2020;573:118842. doi: 10.1016/j.ijpharm.2019.118842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2019.118842</ArticleId>
            <ArticleId IdType="pubmed">31759109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, et al.  Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80:4986–4997. doi: 10.1158/0008-5472.CAN-19-2568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-19-2568</ArticleId>
            <ArticleId IdType="pubmed">32973082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, et al.  Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337:1231–1235. doi: 10.1126/science.1220834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1220834</ArticleId>
            <ArticleId IdType="pmc">PMC3677224</ArticleId>
            <ArticleId IdType="pubmed">22837387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andre F, Ranson M, Dean E, Varga A, van der Noll R, Stockman PK, Ghiorghiu D, Kilgour E, Smith PD, Macpherson M, et al.  Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Cancer Res. 2013;73:LB–145.</Citation>
        </Reference>
        <Reference>
          <Citation>Takahashi Y, Akahane T, Sawada T, Ikeda H, Tempaku A, Yamauchi S, Nishihara H, Tanaka S, Nitta K, Ide W, et al.  Adult classical glioblastoma with a BRAF V600E mutation. World J Surg Oncol. 2015;13:100. doi: 10.1186/s12957-015-0521-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-015-0521-x</ArticleId>
            <ArticleId IdType="pmc">PMC4358908</ArticleId>
            <ArticleId IdType="pubmed">25885250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tosuner Z, Geçer MÖ, Hatiboğlu MA, Abdallah A, Turna S. BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma. Oncol Lett. 2018;16:2402–2408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6036552</ArticleId>
            <ArticleId IdType="pubmed">30013630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, et al.  BRAF activation induces transformation and then senescence in human neural stem cells: A pilocytic astrocytoma model. Clin Cancer Res. 2011;17:3590–3599. doi: 10.1158/1078-0432.CCR-10-3349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-3349</ArticleId>
            <ArticleId IdType="pmc">PMC4086658</ArticleId>
            <ArticleId IdType="pubmed">21636552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behling F, Schittenhelm J. Oncogenic BRAF alterations and their role in brain tumors. Cancers (Basel) 2019;11:794. doi: 10.3390/cancers11060794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11060794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385–394. doi: 10.1158/1535-7163.MCT-10-0799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-10-0799</ArticleId>
            <ArticleId IdType="pubmed">21388974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima N, Nobusawa S, Nakata S, Nakada M, Yamazaki T, Matsumura N, Harada K, Matsuda H, Funata N, Nagai S, et al.  BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: A histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol. 2018;28:663–673. doi: 10.1111/bpa.12572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bpa.12572</ArticleId>
            <ArticleId IdType="pmc">PMC8028676</ArticleId>
            <ArticleId IdType="pubmed">29105198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, et al.  Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28:2581–2587. doi: 10.1093/annonc/mdx339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx339</ArticleId>
            <ArticleId IdType="pmc">PMC5834156</ArticleId>
            <ArticleId IdType="pubmed">28961848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, et al.  Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncol Rep. 2017;38:3291–3296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5783574</ArticleId>
            <ArticleId IdType="pubmed">29039591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo PYM, Lam TC, Pu JKS, Li LF, Leung RCY, Ho JMK, Zhung JTF, Wong B, Chan TSK, Loong HHF, Ng HK. Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: A report of two cases. Oncotarget. 2019;10:3818–3826. doi: 10.18632/oncotarget.26932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.26932</ArticleId>
            <ArticleId IdType="pmc">PMC6557198</ArticleId>
            <ArticleId IdType="pubmed">31217909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiff D, Sarkaria J. Dasatinib in recurrent glioblastoma: Failure as a teacher. Neuro Oncol. 2015;17:910–911. doi: 10.1093/neuonc/nov086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov086</ArticleId>
            <ArticleId IdType="pmc">PMC5762007</ArticleId>
            <ArticleId IdType="pubmed">25964312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and anti-proliferative effects of dasatinib. Cancer Res. 2009;69:3173–3179. doi: 10.1158/0008-5472.CAN-08-3390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-3390</ArticleId>
            <ArticleId IdType="pmc">PMC2749524</ArticleId>
            <ArticleId IdType="pubmed">19318569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, et al.  A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019;125:3790–3800. doi: 10.1002/cncr.32340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.32340</ArticleId>
            <ArticleId IdType="pmc">PMC6788934</ArticleId>
            <ArticleId IdType="pubmed">31290996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava S, Jackson C, Kim T, Choi J, Lim M. A characterization of dendritic cells and their role in immunotherapy in glioblastoma: From preclinical studies to clinical trials. Cancers. 2019;11:537. doi: 10.3390/cancers11040537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11040537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, et al.  A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 2019;25:5799–5807. doi: 10.1158/1078-0432.CCR-19-0261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-0261</ArticleId>
            <ArticleId IdType="pmc">PMC8132111</ArticleId>
            <ArticleId IdType="pubmed">31320597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polson ES, Kuchler VB, Abbosh C, Ross EM, Mathew RK, Beard HA, da Silva B, Holding AN, Ballereau S, Chuntharpursat-Bon E, et al.  KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Sci Transl Med. 2018;10:eaar2718. doi: 10.1126/scitranslmed.aar2718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aar2718</ArticleId>
            <ArticleId IdType="pubmed">30111643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruslova A, Cavazos DA, Miller JR, Breitbart E, Cohen YC, Bangio L, Yakov N, Soundararajan A, Floyd JR, Brenner AJ. VB-111: A novel anti-vascular therapeutic for glioblastoma multiforme. J Neurooncol. 2015;124:365–372. doi: 10.1007/s11060-015-1853-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-015-1853-7</ArticleId>
            <ArticleId IdType="pmc">PMC4584173</ArticleId>
            <ArticleId IdType="pubmed">26108658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, et al.  Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: Results of a phase I/II study. Neuro Oncol. 2020;22:694–704. doi: 10.1093/neuonc/noz231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz231</ArticleId>
            <ArticleId IdType="pmc">PMC7229257</ArticleId>
            <ArticleId IdType="pubmed">31844886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomized, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–1385. doi: 10.1016/S1470-2045(17)30517-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(17)30517-X</ArticleId>
            <ArticleId IdType="pubmed">28844499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, et al.  Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): Results of a double-blind randomized phase II trial. Clin Cancer Res. 2020;26:1586–1594. doi: 10.1158/1078-0432.CCR-18-1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1140</ArticleId>
            <ArticleId IdType="pubmed">32034072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intrace-rebral melanoma. Neurosurgery. 2002;50:158–166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: The game is not over yet. Oncotarget. 2017;8:91779–91794. doi: 10.18632/oncotarget.21586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.21586</ArticleId>
            <ArticleId IdType="pmc">PMC5710964</ArticleId>
            <ArticleId IdType="pubmed">29207684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–1867. doi: 10.1056/NEJMoa1602252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1602252</ArticleId>
            <ArticleId IdType="pmc">PMC5564292</ArticleId>
            <ArticleId IdType="pubmed">27718784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, et al.  Effect of nivolumab vs bevaci-zumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1003–1010. doi: 10.1001/jamaoncol.2020.1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2020.1024</ArticleId>
            <ArticleId IdType="pmc">PMC7243167</ArticleId>
            <ArticleId IdType="pubmed">32437507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson JH, Padula Omuro AM, Preusser M, Lim M, Butowski NA, Cloughesy TF, Strauss LC, Latek RR, Paliwal P, Weller M, Reardon DA. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. J Clin Oncol. 2016;34:TPS2079. doi: 10.1200/JCO.2016.34.15_suppl.TPS2079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.34.15_suppl.TPS2079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, De Groot JF, Nghiemphu PL, Kaley TJ, Colman H, Gaffey SC, et al.  Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol. 2018;36:2006. doi: 10.1200/JCO.2018.36.15_suppl.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.2006</ArticleId>
            <ArticleId IdType="pubmed">29763342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, et al.  Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019;25:470–476. doi: 10.1038/s41591-018-0339-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0339-5</ArticleId>
            <ArticleId IdType="pubmed">30742120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477–486. doi: 10.1038/s41591-018-0337-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0337-7</ArticleId>
            <ArticleId IdType="pmc">PMC6408961</ArticleId>
            <ArticleId IdType="pubmed">30742122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009;52:4981–5004. doi: 10.1021/jm9002395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm9002395</ArticleId>
            <ArticleId IdType="pmc">PMC2888655</ArticleId>
            <ArticleId IdType="pubmed">19610618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002;62:200–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11782378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Shen F, Ma P, Hui H, Pei S, Chen M, Wang Z, Zhou W, Jin B. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo. Mol Med Rep. 2015;12:5641–5646. doi: 10.3892/mmr.2015.4129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2015.4129</ArticleId>
            <ArticleId IdType="pmc">PMC4581800</ArticleId>
            <ArticleId IdType="pubmed">26238593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osher E, Macaulay VM. Therapeutic targeting of the IGF axis. Cells. 2019;8:895. doi: 10.3390/cells8080895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8080895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes PW, Vail ME, Gan HK, Scott AM. Antibody targeting of eph receptors in cancer. Pharmaceuticals. 2020;13:88. doi: 10.3390/ph13050088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph13050088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderton M, van der Meulen E, Blumenthal MJ, Schäfer G. The role of the Eph receptor family in tumorigenesis. Cancers (Basel) 2021;13:206. doi: 10.3390/cancers13020206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13020206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, et al.  The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell. 2012;22:765–780. doi: 10.1016/j.ccr.2012.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.11.005</ArticleId>
            <ArticleId IdType="pmc">PMC3922047</ArticleId>
            <ArticleId IdType="pubmed">23238013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005;3:541–551. doi: 10.1158/1541-7786.MCR-05-0056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-05-0056</ArticleId>
            <ArticleId IdType="pubmed">16254188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, et al.  KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016;50:123–131. doi: 10.1016/j.leukres.2016.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.leukres.2016.09.012</ArticleId>
            <ArticleId IdType="pubmed">27736729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83–96. doi: 10.1038/nrc3430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3430</ArticleId>
            <ArticleId IdType="pmc">PMC4161369</ArticleId>
            <ArticleId IdType="pubmed">23303139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avci NG, Ebrahimzadeh-Pustchi S, Akay YM, Esquenazi Y, Tandon N, Zhu JJ, Akay M. NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways. Sci Rep. 2020;10:13352. doi: 10.1038/s41598-020-70392-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-70392-5</ArticleId>
            <ArticleId IdType="pmc">PMC7414229</ArticleId>
            <ArticleId IdType="pubmed">32770097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck S, Jin X, Sohn YW, Kim JK, Kim SH, Yin J, Pian X, Kim SC, Nam DH, Choi YJ, Kim H. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells. 2011;31:9–15. doi: 10.1007/s10059-011-0008-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10059-011-0008-8</ArticleId>
            <ArticleId IdType="pmc">PMC3906874</ArticleId>
            <ArticleId IdType="pubmed">21193962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olympios N, Gilard V, Marguet F, Clatot F, Di Fiore F, Fontanilles M. TERT promoter alterations in glioblastoma: A systematic review. Cancers (Basel) 2021;13:1147. doi: 10.3390/cancers13051147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13051147</ArticleId>
            <ArticleId IdType="pmc">PMC7962450</ArticleId>
            <ArticleId IdType="pubmed">33800183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metro G, Pierini T, La Starza R.  TERT Mutations in Glioma: ESMO Biomarker Factsheet. European Society for Medical Oncology; Lugano: 2019.   https://oncologypro.esmo.org/education-library/factsheets-on-biomarkers/tert-mutations-in-glioma. Accessed January 25, 2019.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35445737</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1791-2423</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>60</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>International journal of oncology</Title>
          <ISOAbbreviation>Int J Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review).</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">69</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3892/ijo.2022.5359</ELocationID>
        <Abstract>
          <AbstractText>Glioblastoma multiforme (GBM) is the most aggressive type of primary brain tumor and is associated with a poor clinical prognosis. Despite the progress in the understanding of the molecular and genetic changes that promote tumorigenesis, effective treatment options are limited. The present review intended to identify and summarize major signaling pathways and genetic abnormalities involved in the pathogenesis of GBM, as well as therapies that target these pathways. Glioblastoma remains a difficult to treat tumor; however, in the last two decades, significant improvements in the understanding of GBM biology have enabled advances in available therapeutics. Significant genomic events and signaling pathway disruptions (NF‑κB, Wnt, PI3K/AKT/mTOR) involved in the formation of GBM were discussed. Current therapeutic options may only marginally prolong survival and the current standard of therapy cures only a small fraction of patients. As a result, there is an unmet requirement for further study into the processes of glioblastoma pathogenesis and the discovery of novel therapeutic targets in novel signaling pathways implicated in the evolution of glioblastoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Khabibov</LastName>
            <ForeName>Marsel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, I. M. Sechenov First Moscow State Medical University, 119992 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Garifullin</LastName>
            <ForeName>Airat</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology, Bashkir State Medical University, 450000 Ufa, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Boumber</LastName>
            <ForeName>Yanis</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Hematology/Oncology at The Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Khaddour</LastName>
            <ForeName>Karam</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Hematology and Oncology, University of Illinois at Chicago, Chicago, IL 60612, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fernandez</LastName>
            <ForeName>Manuel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Khamitov</LastName>
            <ForeName>Firat</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology, Bashkir State Medical University, 450000 Ufa, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Khalikova</LastName>
            <ForeName>Larisa</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Histology, Bashkir State Medical University, 450000 Ufa, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuznetsova</LastName>
            <ForeName>Natalia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neuro‑Oncology, National Medical Research Center for Oncology, 344037 Rostov‑on‑Don, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kit</LastName>
            <ForeName>Oleg</ForeName>
            <Initials>O</Initials>
            <AffiliationInfo>
              <Affiliation>Abdominal Oncology Department, National Medical Research Center for Oncology, 344037 Rostov‑on‑Don, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kharin</LastName>
            <ForeName>Leonid</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Abdominal Oncology Department, National Medical Research Center for Oncology, 344037 Rostov‑on‑Don, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>P30 CA060553</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 CA218802</GrantID>
            <Acronym>CA</Acronym>
            <Agency>NCI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Oncol</MedlineTA>
        <NlmUniqueID>9306042</NlmUniqueID>
        <ISSNLinking>1019-6439</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">glioblastoma</Keyword>
        <Keyword MajorTopicYN="Y">immunotherapy</Keyword>
        <Keyword MajorTopicYN="Y">mutations</Keyword>
        <Keyword MajorTopicYN="Y">signaling pathways</Keyword>
        <Keyword MajorTopicYN="Y">targeted therapy</Keyword>
        <Keyword MajorTopicYN="Y">tumor treating fields</Keyword>
      </KeywordList>
      <CoiStatement>YB has been a speaker for Amgen and Regeneron and has been an Advisor/Board Member for Alphageneron, G1 Therapeutics and Jazz Pharmaceuticals. The remaining authors have no competing interests to declare.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>11</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
          <Hour>8</Hour>
          <Minute>46</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35445737</ArticleId>
        <ArticleId IdType="pmc">PMC9084550</ArticleId>
        <ArticleId IdType="doi">10.3892/ijo.2022.5359</ArticleId>
        <ArticleId IdType="pii">69</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, Trétarre B, Bauchet F, Duffau H, Taillandier L, Bauchet L. Epidemiology for primary brain tumors: A nationwide population-based study. J Neurooncol. 2017;131:525–546. doi: 10.1007/s11060-016-2318-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-016-2318-3</ArticleId>
            <ArticleId IdType="pubmed">27853959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tykocki T, Eltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13. doi: 10.1016/j.jocn.2018.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jocn.2018.05.002</ArticleId>
            <ArticleId IdType="pubmed">29801989</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faleh TA, Juweid M. Epidemiology and outcome of glioblastoma. Exon Publications. 2017:143–153.</Citation>
        </Reference>
        <Reference>
          <Citation>Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, et al.  The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol. 2021;23:1231–1251. doi: 10.1093/neuonc/noab106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noab106</ArticleId>
            <ArticleId IdType="pmc">PMC8328013</ArticleId>
            <ArticleId IdType="pubmed">34185076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization  . Histological classification of tumors of the central nervous system. Lyon, France: IARC; 2016. </Citation>
        </Reference>
        <Reference>
          <Citation>Zong H, Parada LF, Baker SJ. Cell of origin for malignant gliomas and its implication in therapeutic development. Cold Spring Harb Perspect Biol. 2015;7:a020610. doi: 10.1101/cshperspect.a020610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a020610</ArticleId>
            <ArticleId IdType="pmc">PMC4448618</ArticleId>
            <ArticleId IdType="pubmed">25635044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pombo Antunes AR, Scheyltjens I, Duerinck J, Neyns B, Movahedi K, Van Ginderachter JA. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. Elife. 2020;9:e52176. doi: 10.7554/eLife.52176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.52176</ArticleId>
            <ArticleId IdType="pmc">PMC7000215</ArticleId>
            <ArticleId IdType="pubmed">32014107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khaddour K, Johanns TM, Ansstas G. The landscape of novel therapeutics and challenges in glioblastoma multiforme: Contemporary state and future directions. Pharmaceuticals (Basel) 2020;13:389. doi: 10.3390/ph13110389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph13110389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–996. doi: 10.1056/NEJMoa043330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa043330</ArticleId>
            <ArticleId IdType="pubmed">15758009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, et al.  Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2017.18718</ArticleId>
            <ArticleId IdType="pmc">PMC5820703</ArticleId>
            <ArticleId IdType="pubmed">29260225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, et al.  A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE) Neuro Oncol. 2020;22:705–717. doi: 10.1093/neuonc/noz232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz232</ArticleId>
            <ArticleId IdType="pmc">PMC7229248</ArticleId>
            <ArticleId IdType="pubmed">31844890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nabors LB, Portnow J, Ahluwalia M, Baehring J, Brem H, Brem S, Butowski N, Campian JL, Clark SW, Fabiano AJ, et al.  Central nervous system cancers, Version 3.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18:1537–1570. doi: 10.6004/jnccn.2020.0052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.6004/jnccn.2020.0052</ArticleId>
            <ArticleId IdType="pubmed">33152694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lombardi G, De Salvo GL, Brandes AA, Eoli M, Rudà R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, et al.  Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): A multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019;20:110–119. doi: 10.1016/S1470-2045(18)30675-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30675-2</ArticleId>
            <ArticleId IdType="pubmed">30522967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grothey A, Blay JY, Pavlakis N, Yoshino T, Bruix J. Evolving role of regorafenib for the treatment of advanced cancers. Cancer Treat Rev. 2020;86:101993. doi: 10.1016/j.ctrv.2020.101993.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctrv.2020.101993</ArticleId>
            <ArticleId IdType="pubmed">32199197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro Oncol. 2019;21(Suppl 5):v1–v100. doi: 10.1093/neuonc/noz150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz150</ArticleId>
            <ArticleId IdType="pmc">PMC6823730</ArticleId>
            <ArticleId IdType="pubmed">31675094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levin VA, Leibel SA, Gutin PH.  Neoplasms of the central nervous system In: Cancer: Principles and Practice of Oncology. 6th edition. Lippincott Williams and Wilkins; Philadelphia, PA: 2001. pp. 2100–2160.</Citation>
        </Reference>
        <Reference>
          <Citation>Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al.  Effects of radiotherapy with concomitant and adjuvant temozolo-mide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–466. doi: 10.1016/S1470-2045(09)70025-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(09)70025-7</ArticleId>
            <ArticleId IdType="pubmed">19269895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee ShU. Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18:3–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5563115</ArticleId>
            <ArticleId IdType="pubmed">28239999</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amirian ES, Ostrom QT, Armstrong GN, Lai RK, Gu X, Jacobs DI, Jalali A, Claus EB, Barnholtz-Sloan JS, Il'yasova D, et al.  Aspirin, NSAIDs, and Glioma Risk: Original data from the glioma international Case-Control study and a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2019;28:555–562.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6401283</ArticleId>
            <ArticleId IdType="pubmed">30482874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheurer ME, El-Zein R, Thompson PA, Aldape KD, Levin VA, Gilbert MR, Weinberg JS, Bondy ML. Long-term anti-inflam-matory and antihistamine medication use and adult glioma risk. Cancer Epidemiol Biomarkers Prev. 2008;17:1277–1281. doi: 10.1158/1055-9965.EPI-07-2621.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1055-9965.EPI-07-2621</ArticleId>
            <ArticleId IdType="pmc">PMC6436627</ArticleId>
            <ArticleId IdType="pubmed">18483351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS, HCMV and Gliomas Symposium  Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 2012;14:246–255. doi: 10.1093/neuonc/nor227.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nor227</ArticleId>
            <ArticleId IdType="pmc">PMC3280809</ArticleId>
            <ArticleId IdType="pubmed">22319219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Söderberg-Nauclér C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N Engl J Med. 2013;369:985–986. doi: 10.1056/NEJMc1302145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1302145</ArticleId>
            <ArticleId IdType="pubmed">24004141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bei R, Marzocchella L, Turriziani M. The use of temozolo-mide for the treatment of malignant tumors: Clinical evidence and molecular mechanisms of action. Recent Pat Anticancer Drug Discov. 2010;5:172–187. doi: 10.2174/157489210791760526.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/157489210791760526</ArticleId>
            <ArticleId IdType="pubmed">20594183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lacal PM, D'Atri S, Orlando L, Bonmassar E, Graziani G. In vitro inactivation of human O6-alkylguanine DNA alkyl-transferase by antitumor triazene compounds. J Pharmacol Exp Ther. 1996;279:416–422.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8859021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Zambruno G, Bonmassar E, Jiricny J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol Pharmacol. 1998;54:334–341. doi: 10.1124/mol.54.2.334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/mol.54.2.334</ArticleId>
            <ArticleId IdType="pubmed">9687575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP. Depletion of O 6-alkylguanine-DNA alkyltrans-ferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer. 1993;67:1299–1302. doi: 10.1038/bjc.1993.241.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.1993.241</ArticleId>
            <ArticleId IdType="pmc">PMC1968485</ArticleId>
            <ArticleId IdType="pubmed">8512814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma Multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;17:105780. doi: 10.1016/j.phrs.2021.105780.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2021.105780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grossmann P, Narayan V, Chang K, Rahman R, Abrey L, Reardon DA, Schwartz LH, Wen PY, Alexander BM, Huang R, Aerts HJWL. Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2017;19:1688–1697. doi: 10.1093/neuonc/nox092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nox092</ArticleId>
            <ArticleId IdType="pmc">PMC5716072</ArticleId>
            <ArticleId IdType="pubmed">28499022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733–4740. doi: 10.1200/JCO.2008.19.8721.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2008.19.8721</ArticleId>
            <ArticleId IdType="pubmed">19720927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther. 2011;28:334–340. doi: 10.1007/s12325-011-0007-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12325-011-0007-3</ArticleId>
            <ArticleId IdType="pubmed">21432029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, AldapeHoward Colman KD, Chakravarti A, Jeraj R, Armstrong TS, Scott Wefel J, et al.  RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM) J Clin Oncol. 2013;31:1. doi: 10.1200/jco.2013.31.15_suppl.1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/jco.2013.31.15_suppl.1</ArticleId>
            <ArticleId IdType="pubmed">23129739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diaz RJ, Ali S, Qadir MG, De La Fuente MI, Ivan ME, Komotar RJ. The role of bevacizumab in the treatment of glio-blastoma. J Neurooncol. 2017;133:455–467. doi: 10.1007/s11060-017-2477-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-017-2477-x</ArticleId>
            <ArticleId IdType="pubmed">28527008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Taal W, Oosterkamp HM, Walenkamp AM, Dubbink HJ, Beerepoot LV, Hanse MC, Buter J, Honkoop AH, Boerman D, de Vos FY, et al.  Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 Trial. Lancet Oncol. 2014;15:943–953. doi: 10.1016/S1470-2045(14)70314-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)70314-6</ArticleId>
            <ArticleId IdType="pubmed">25035291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brandsma D, van den Bent MJ. Pseudoprogression and pseu-doresponse in the treatment of gliomas. Curr Opin Neurol. 2009;22:633–638. doi: 10.1097/WCO.0b013e328332363e.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0b013e328332363e</ArticleId>
            <ArticleId IdType="pubmed">19770760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, et al.  Updated response assessment criteria for high-grade gliomas: Response assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28:1963–1972. doi: 10.1200/JCO.2009.26.3541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2009.26.3541</ArticleId>
            <ArticleId IdType="pubmed">20231676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, Mason W, Mikkelsen T, Phuphanich S, Ashby LS, et al.  Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol. 2013;31:3212. doi: 10.1200/JCO.2012.47.2464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2012.47.2464</ArticleId>
            <ArticleId IdType="pmc">PMC4021043</ArticleId>
            <ArticleId IdType="pubmed">23940216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, et al.  Phase II study of aflibercept in recurrent malignant glioma: A North American Brain Tumor Consortium study. J Clin Oncol. 2011;29:2689–2995. doi: 10.1200/JCO.2010.34.1636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2010.34.1636</ArticleId>
            <ArticleId IdType="pmc">PMC3139373</ArticleId>
            <ArticleId IdType="pubmed">21606416</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, et al.  Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial. JAMA. 2015;314:2535–2543. doi: 10.1001/jama.2015.16669.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2015.16669</ArticleId>
            <ArticleId IdType="pubmed">26670971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabian D, Guillermo Prieto Eibl MDP, Alnahhas I, Sebastian N, Giglio P, Puduvalli V, Gonzalez J, Palmer JD. Treatment of glioblastoma (GBM) with the addition of tumor-treating fields (TTF): A review. Cancers (Basel) 2019;11:174. doi: 10.3390/cancers11020174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11020174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown TJ, Brennan MC, Li M, Church EW, Brandmeir NJ, Rakszawski KL, Patel AS, Rizk EB, Suki D, Sawaya R, Glantz M. Association of the extent of resection with survival in glioblastoma: A systematic review and meta-analysis. JAMA Oncol. 2016;2:1460–1469. doi: 10.1001/jamaoncol.2016.1373.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2016.1373</ArticleId>
            <ArticleId IdType="pmc">PMC6438173</ArticleId>
            <ArticleId IdType="pubmed">27310651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noorbakhsh A, Tang JA, Marcus LP, McCutcheon B, Gonda DD, Schallhorn CS, Talamini MA, Chang DC, Carter BS, Chen CC. Gross-total resection outcomes in an elderly population with glioblastoma: A SEER-based analysis. J Neurosurg. 2014;120:31–39. doi: 10.3171/2013.9.JNS13877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2013.9.JNS13877</ArticleId>
            <ArticleId IdType="pubmed">24205904</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eigenbrod S, Trabold R, Brucker D, Erös C, Egensperger R, La Fougere C, Göbel W, Rühm A, Kretzschmar HA, Tonn JC, et al.  Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients. Acta Neurochir (Wien) 2014;156:1427–1440. doi: 10.1007/s00701-014-2073-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00701-014-2073-1</ArticleId>
            <ArticleId IdType="pubmed">24792966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stummer W, Tonn JC, Mehdorn HM, Nestler U, Franz K, Goetz C, Bink A, Pichlmeier U, ALA-Glioma Study Group  Counterbalancing risks and gains from extended resections in malignant glioma surgery: A supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg. 2011;114:613–623. doi: 10.3171/2010.3.JNS097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3171/2010.3.JNS097</ArticleId>
            <ArticleId IdType="pubmed">20397896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Berntsen EM, Gulati S, Solheim O, Kvistad KA, Torp SH, Selbekk T, Unsgård G, Håberg AK. Functional magnetic resonance imaging and diffusion tensor tractography incorporated into an intraoperative 3-dimensional ultrasound-based neuronavigation system: Impact on therapeutic strategies, extent of resection, and clinical outcome. Neurosurgery. 2010;67:251–264. doi: 10.1227/01.NEU.0000371731.20246.AC.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1227/01.NEU.0000371731.20246.AC</ArticleId>
            <ArticleId IdType="pubmed">20644410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ringel F, Pape H, Sabel M, Krex D, Bock HC, Misch M, Weyerbrock A, Westermaier T, Senft C, Schucht P, et al.  Clinical benefit from resection of recurrent glioblastomas: Results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro Oncol. 2016;18:96–104. doi: 10.1093/neuonc/nov145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov145</ArticleId>
            <ArticleId IdType="pmc">PMC4677413</ArticleId>
            <ArticleId IdType="pubmed">26243790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuccarini M, Giuliani P, Ziberi S, Carluccio M, Iorio PD, Caciagli F, Ciccarelli R. The role of Wnt signal in glioblastoma development and progression: A possible new pharmacological target for the therapy of this tumor. Genes (Basel) 2018;9:105. doi: 10.3390/genes9020105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/genes9020105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018;12:3–20. doi: 10.1002/1878-0261.12155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1878-0261.12155</ArticleId>
            <ArticleId IdType="pmc">PMC5748484</ArticleId>
            <ArticleId IdType="pubmed">29124875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao A, Brenneman B, Floyd D, Comeau L, Spurio K, Olmez I, Lee J, Nakano I, Godlewski J, Bronisz A, et al.  Statins affect human glioblastoma and other cancers through TGF-β inhibition. Oncotarget. 2019;10:1716–1728. doi: 10.18632/oncotarget.26733.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.26733</ArticleId>
            <ArticleId IdType="pmc">PMC6422202</ArticleId>
            <ArticleId IdType="pubmed">30899443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keunen O, Johansson M, Oudin A, Sanzey M, Rahim SA, Fack F, Thorsen F, Taxt T, Bartos M, Jirik R, et al.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci USA. 2011;108:3749–3754. doi: 10.1073/pnas.1014480108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1014480108</ArticleId>
            <ArticleId IdType="pmc">PMC3048093</ArticleId>
            <ArticleId IdType="pubmed">21321221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cyclin-dependent kinase inhibitor 2A. GeneCards. Weizmann institute of science;  Retrieved December 15, 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Albensi BC. What is nuclear factor kappa B (NF-κB) doing in and to the mitochondrion? Front Cell Dev Biol. 2019;7:154. doi: 10.3389/fcell.2019.00154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fcell.2019.00154</ArticleId>
            <ArticleId IdType="pmc">PMC6692429</ArticleId>
            <ArticleId IdType="pubmed">31448275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia L, Tan S, Zhou Y, Lin J, Wang H, Oyang L, Tian Y, Liu L, Su M, Wang H, et al.  Role of the NFκB-signaling pathway in cancer. Onco Targets Ther. 2018;11:2063–2073. doi: 10.2147/OTT.S161109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/OTT.S161109</ArticleId>
            <ArticleId IdType="pmc">PMC5905465</ArticleId>
            <ArticleId IdType="pubmed">29695914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia Y, Shen S, Verma IM. NF-κB, an active player in human cancers. Cancer Immunol Res. 2014;2:823–830. doi: 10.1158/2326-6066.CIR-14-0112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-14-0112</ArticleId>
            <ArticleId IdType="pmc">PMC4155602</ArticleId>
            <ArticleId IdType="pubmed">25187272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L. PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7:33440–33450. doi: 10.18632/oncotarget.7961.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.7961</ArticleId>
            <ArticleId IdType="pmc">PMC5078108</ArticleId>
            <ArticleId IdType="pubmed">26967052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget. 2010;1:530. doi: 10.18632/oncotarget.188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.188</ArticleId>
            <ArticleId IdType="pmc">PMC3248125</ArticleId>
            <ArticleId IdType="pubmed">21317449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crespo I, Vital AL, Gonzalez-Tablas M, Patino Mdel C, Otero A, Lopes MC, de Oliveira C, Domingues P, Orfao A, Tabernero MD. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol. 2015;185:1820–1833. doi: 10.1016/j.ajpath.2015.02.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ajpath.2015.02.023</ArticleId>
            <ArticleId IdType="pubmed">25976245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balça-Silva J, Matias D, Carmo AD, Sarmento-Ribeiro AB, Lopes MC, Moura-Neto V. Cellular and molecular mechanisms of glioblastoma malignancy: Implications in resistance and therapeutic strategies. Semin Cancer Biol. 2019;58:130–141. doi: 10.1016/j.semcancer.2018.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semcancer.2018.09.007</ArticleId>
            <ArticleId IdType="pubmed">30266571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rajesh Y, Pal I, Banik P, Chakraborty S, Borkar SA, Dey G, Mukherjee A, Mandal M. Insights into molecular therapy of glioma: Current challenges and next generation blueprint. Acta Pharmacol Sin. 2017;38:591–613. doi: 10.1038/aps.2016.167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/aps.2016.167</ArticleId>
            <ArticleId IdType="pmc">PMC5457688</ArticleId>
            <ArticleId IdType="pubmed">28317871</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cancer Genome Atlas, Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455:1061–1068. doi: 10.1038/nature07385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature07385</ArticleId>
            <ArticleId IdType="pmc">PMC2671642</ArticleId>
            <ArticleId IdType="pubmed">18772890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M. MGMT promoter methylation cutoff with safety margin for selecting glioblastoma patients into trials omitting temozolomide: A pooled analysis of four clinical trials. Clin Cancer Res. 2019;25:1809–1816. doi: 10.1158/1078-0432.CCR-18-3181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-3181</ArticleId>
            <ArticleId IdType="pmc">PMC8127866</ArticleId>
            <ArticleId IdType="pubmed">30514777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chai RC, Zhang KN, Chang YZ, Wu F, Liu YQ, Zhao Z, Wang KY, Chang YH, Jiang T, Wang YZ. Systematically characterize the clinical and biological significances of 1p19q genes in 1p/19q non-codeletion glioma. Carcinogenesis. 2019;40:1229–1239. doi: 10.1093/carcin/bgz102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/carcin/bgz102</ArticleId>
            <ArticleId IdType="pubmed">31157866</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, et al.  Glioblastoma with an oligodendroglioma component: Distinct clinical behavior, genetic alterations, and outcome. Neuro Oncol. 2012;14:518–525. doi: 10.1093/neuonc/nor232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nor232</ArticleId>
            <ArticleId IdType="pmc">PMC3309852</ArticleId>
            <ArticleId IdType="pubmed">22326863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clark KH, Villano JL, Nikiforova MN, Hamilton RL, Horbinski C. 1p/19q testing has no significance in the workup of glioblastomas. Neuropathol Appl Neurobiol. 2013;39:706–717. doi: 10.1111/nan.12031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/nan.12031</ArticleId>
            <ArticleId IdType="pmc">PMC4095883</ArticleId>
            <ArticleId IdType="pubmed">23363074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al.  Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–339. doi: 10.1038/nature12634.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature12634</ArticleId>
            <ArticleId IdType="pmc">PMC3927368</ArticleId>
            <ArticleId IdType="pubmed">24132290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brosh R, Rotter V. When mutants gain new powers: News from the mutant p53 field. Nat Rev Cancer. 2009;9:701–713. doi: 10.1038/nrc2693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2693</ArticleId>
            <ArticleId IdType="pubmed">19693097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al.  Erratum: The somatic genomic landscape of glioblastoma. Cell. 2013;155:462–477. doi: 10.1016/j.cell.2013.09.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.09.034</ArticleId>
            <ArticleId IdType="pmc">PMC3910500</ArticleId>
            <ArticleId IdType="pubmed">24120142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu F, Huang J, Liu X, Cheng Q, Luo C, Liu Z. CTLA-4 correlates with immune and clinical characteristics of glioma. Cancer Cell Int. 2020;20:7. doi: 10.1186/s12935-019-1085-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12935-019-1085-6</ArticleId>
            <ArticleId IdType="pmc">PMC6945521</ArticleId>
            <ArticleId IdType="pubmed">31911758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garofano L, Migliozzi S, Oh YT, D'Angelo F, Najac RD, Ko A, Frangaj B, Caruso FP, Yu K, Yuan J, et al.  Pathway-based clas-sification of glioblastoma uncovers a mitochondrial subtype with therapeutic vulnerabilities. Nat Cancer. 2021;2:141–156. doi: 10.1038/s43018-020-00159-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-020-00159-4</ArticleId>
            <ArticleId IdType="pmc">PMC7935068</ArticleId>
            <ArticleId IdType="pubmed">33681822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu VM, O'Connor KP, Shah AH, Eichberg DG, Luther EM, Komotar RJ, Ivan ME. The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: A systematic review of the contemporary literature. J Neurooncol. 2020;148:221–229. doi: 10.1007/s11060-020-03528-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-020-03528-2</ArticleId>
            <ArticleId IdType="pubmed">32385699</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>William D, Mokri P, Lamp N, Linnebacher M, Classen CF, Erbersdobler A, Schneider B. Amplification of the EGFR gene can be maintained and modulated by variation of EGF concentrations in in vitro models of glioblastoma multiforme. PLoS One. 2017;12:e0185208. doi: 10.1371/journal.pone.0185208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0185208</ArticleId>
            <ArticleId IdType="pmc">PMC5608330</ArticleId>
            <ArticleId IdType="pubmed">28934307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Felsberg J, Hentschel B, Kaulich K, Gramatzki D, Zacher A, Malzkorn B, Kamp M, Sabel M, Simon M, Westphal M, et al.  Epidermal growth factor receptor variant III (EGFRvIII) positivity in EGFR-amplified glioblastomas: Prognostic role and comparison between primary and recurrent tumors. Clin Cancer Res. 2017;23:6846–6855. doi: 10.1158/1078-0432.CCR-17-0890.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-17-0890</ArticleId>
            <ArticleId IdType="pubmed">28855349</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>An Z, Aksoy O, Zheng T, Fan QW, Weiss WA. Epidermal growth factor receptor and EGFRvIII in glioblastoma: Signaling pathways and targeted therapies. Oncogene. 2018;37:1561–1575. doi: 10.1038/s41388-017-0045-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-017-0045-7</ArticleId>
            <ArticleId IdType="pmc">PMC5860944</ArticleId>
            <ArticleId IdType="pubmed">29321659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu H, Zong H, Ma C, Ming X, Shang M, Li K, He X, Du H, Cao L. Epidermal growth factor receptor in glioblastoma. Oncol Lett. 2017;14:512–516. doi: 10.3892/ol.2017.6221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/ol.2017.6221</ArticleId>
            <ArticleId IdType="pmc">PMC5494611</ArticleId>
            <ArticleId IdType="pubmed">28693199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De S, Dermawan JK, Stark GR. EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells. Proc Natl Acad Sci USA. 2014;111:11721–11726. doi: 10.1073/pnas.1412390111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1412390111</ArticleId>
            <ArticleId IdType="pmc">PMC4136585</ArticleId>
            <ArticleId IdType="pubmed">25071181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen PØ, Eskilsson E, et al.  EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 2013;125:683–698. doi: 10.1007/s00401-013-1101-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-013-1101-1</ArticleId>
            <ArticleId IdType="pmc">PMC3631314</ArticleId>
            <ArticleId IdType="pubmed">23429996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T, Koizumi F. Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer. 2013;12:31. doi: 10.1186/1476-4598-12-31.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1476-4598-12-31</ArticleId>
            <ArticleId IdType="pmc">PMC3641008</ArticleId>
            <ArticleId IdType="pubmed">23617883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther. 2007;6:1167–1174. doi: 10.1158/1535-7163.MCT-06-0691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-06-0691</ArticleId>
            <ArticleId IdType="pubmed">17363510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cetintas VB, Batada NN. Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment? J Transl Med. 2020;18:45. doi: 10.1186/s12967-020-02219-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12967-020-02219-w</ArticleId>
            <ArticleId IdType="pmc">PMC6993356</ArticleId>
            <ArticleId IdType="pubmed">32000794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, et al.  A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010;12:95–103. doi: 10.1093/neuonc/nop015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nop015</ArticleId>
            <ArticleId IdType="pmc">PMC2940554</ArticleId>
            <ArticleId IdType="pubmed">20150372</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005;353:2012–2024. doi: 10.1056/NEJMoa051918.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa051918</ArticleId>
            <ArticleId IdType="pubmed">16282176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, et al.  RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phy. 2013;85:1206–1211. doi: 10.1016/j.ijrobp.2012.10.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2012.10.008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, James CD, Scheithauer BW, Behrens RJ, Flynn PJ, et al.  Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North central cancer treatment group study N0074. Int J Radiat Oncol Biol Phys. 2011;80:347–353. doi: 10.1016/j.ijrobp.2010.01.070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2010.01.070</ArticleId>
            <ArticleId IdType="pmc">PMC5753591</ArticleId>
            <ArticleId IdType="pubmed">20510539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, Vandenberg S, Brennan C, Johns TG, Bachoo R, Hadwiger P, et al.  Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010;24:1731–1745. doi: 10.1101/gad.1890510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.1890510</ArticleId>
            <ArticleId IdType="pmc">PMC2922502</ArticleId>
            <ArticleId IdType="pubmed">20713517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L, Falini A, De Palma M, Bulfone A, Poliani PL, Galli R. Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 2010;70:7500–7513. doi: 10.1158/0008-5472.CAN-10-2353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-10-2353</ArticleId>
            <ArticleId IdType="pubmed">20858720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, et al.  INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 2020;22:684–693. doi: 10.1093/neuonc/noz222.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz222</ArticleId>
            <ArticleId IdType="pmc">PMC7229258</ArticleId>
            <ArticleId IdType="pubmed">31747009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1:a000034. doi: 10.1101/cshperspect.a000034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/cshperspect.a000034</ArticleId>
            <ArticleId IdType="pmc">PMC2773619</ArticleId>
            <ArticleId IdType="pubmed">20066092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dresselhaus EC, Meffert MK. Cellular specificity of NF-κB function in the nervous system. Front Immunol. 2019;10:1043. doi: 10.3389/fimmu.2019.01043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.01043</ArticleId>
            <ArticleId IdType="pmc">PMC6520659</ArticleId>
            <ArticleId IdType="pubmed">31143184</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedmann-Morvinski D, Narasimamurthy R, Xia Y, Myskiw C, Soda Y, Verma IM. Targeting NF-κB in glioblastoma: A therapeutic approach. Sci Adv. 2016;2:e1501292. doi: 10.1126/sciadv.1501292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciadv.1501292</ArticleId>
            <ArticleId IdType="pmc">PMC4730860</ArticleId>
            <ArticleId IdType="pubmed">26824076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN. Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest. 2004;84:941–951. doi: 10.1038/labinvest.3700123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.3700123</ArticleId>
            <ArticleId IdType="pubmed">15184909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, Aldape K, et al.  EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell. 2012;48:771–784. doi: 10.1016/j.molcel.2012.09.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2012.09.028</ArticleId>
            <ArticleId IdType="pmc">PMC3526114</ArticleId>
            <ArticleId IdType="pubmed">23123196</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap YS, McPherson JR, Ong CK, Rozen SG, The BT, Lee AS, Callen DF. The NF1 gene revisited-from bench to bedside. Oncotarget. 2014;5:5873–5892. doi: 10.18632/oncotarget.2194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.2194</ArticleId>
            <ArticleId IdType="pmc">PMC4171599</ArticleId>
            <ArticleId IdType="pubmed">25026295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schäfer C, Göder A, Beyer M, Kiweler N, Mahendrarajah N, Rauch A, Nikolova T, Stojanovic N, Wieczorek M, Reich TR, et al.  Class I histone deacetylases regulate p53/NF-κB crosstalk in cancer cells. Cell Signal. 2018;29:218–225. doi: 10.1016/j.cellsig.2016.11.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellsig.2016.11.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zanotto-Filho A, Braganhol E, Schröder R, de Souza LH, Dalmolin RJ, Pasquali MA, Gelain DP, Battastini AM, Moreira JC. NFκB inhibitors induce cell death in glioblastomas. Biochem Pharmacol. 2011;81:412–424. doi: 10.1016/j.bcp.2010.10.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2010.10.014</ArticleId>
            <ArticleId IdType="pubmed">21040711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shinoda K, Kuboki S, Shimizu H, Ohtsuka M, Kato A, Yoshitomi H, Furukawa K, Miyazaki M. Pin1 facilitates NF-κ B activation and promotes tumour progression in human hepatocellular carcinoma. Br J Cancer. 2015;113:1323–1331. doi: 10.1038/bjc.2015.272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2015.272</ArticleId>
            <ArticleId IdType="pmc">PMC4815797</ArticleId>
            <ArticleId IdType="pubmed">26461058</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros M, Candido MF, Valera ET, Brassesco MS. The multifaceted NF-kB: Are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors? Cell Mol Life Sci. 2021;78:6161–6200. doi: 10.1007/s00018-021-03906-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00018-021-03906-7</ArticleId>
            <ArticleId IdType="pubmed">34333711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phesse T, Flanagan D, Vincan E. Frizzled7: A promising Achilles' Heel for targeting the Wnt receptor complex to treat cancer. Cancers (Basel) 2016;8:50. doi: 10.3390/cancers8050050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers8050050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao J, Liao Y, Qiu M, Shen W. Wnt/β-catenin signaling in neural stem cell homeostasis and neurological diseases. Neuroscientist. 2021;27:58–72. doi: 10.1177/1073858420914509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1073858420914509</ArticleId>
            <ArticleId IdType="pubmed">32242761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang C, Guo J, Chen H, Yao CJ, Zhuang DX, Wang Y, Tang WJ, Ren G, Yao Y, Wu JS, et al.  Gene mutation profiling of primary glioblastoma through multiple tumor biopsy guided by 1H-magnetic resonance spectroscopy. Int J Clin Exp Pathol. 2015;8:5327–5335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4503105</ArticleId>
            <ArticleId IdType="pubmed">26191234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yun EJ, Kim S, Hsieh JT, Baek ST. Wnt/β-catenin signaling pathway induces autophagy-mediated temozolomide-resistance in human glioblastoma. Cell Death Dis. 2020;11:771. doi: 10.1038/s41419-020-02988-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41419-020-02988-8</ArticleId>
            <ArticleId IdType="pmc">PMC7498596</ArticleId>
            <ArticleId IdType="pubmed">32943609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tompa M, Kalovits F, Nagy A, Kalman B. Contribution of the Wnt pathway to defining biology of glioblastoma. Neuromolecular Med. 2018;20:437–451. doi: 10.1007/s12017-018-8514-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12017-018-8514-x</ArticleId>
            <ArticleId IdType="pubmed">30259273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mori H, Yao Y, Learman BS, Kurozumi K, Ishida J, Ramakrishnan SK, Overmyer KA, Xue X, Cawthorn WP, Reid MA, et al.  Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion. Sci Rep. 2016;6:21520. doi: 10.1038/srep21520.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/srep21520</ArticleId>
            <ArticleId IdType="pmc">PMC4748282</ArticleId>
            <ArticleId IdType="pubmed">26861754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rampazzo E, Persano L, Pistollato F, Moro E, Frasson C, Porazzi P, Della Puppa A, Bresolin S, Battilana G, Indraccolo S, et al.  Wnt activation promotes neuronal differentiation of glioblastoma. Cell Death Dis. 2013;4:e500. doi: 10.1038/cddis.2013.32.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/cddis.2013.32</ArticleId>
            <ArticleId IdType="pmc">PMC4098797</ArticleId>
            <ArticleId IdType="pubmed">23429286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu C, Takada K, Di Z. Targeting Wnt/β-catenin pathway for drug therapy. Med Drug Discovery. 2020;8:100066. doi: 10.1016/j.medidd.2020.100066.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.medidd.2020.100066</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diamond JR, Becerra C, Richards D, Mita A, Osborne C, O'Shaughnessy J, Zhang C, Henner R, Kapoun AM, Xu L, et al.  Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020;184:53–62. doi: 10.1007/s10549-020-05817-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-020-05817-w</ArticleId>
            <ArticleId IdType="pmc">PMC7572714</ArticleId>
            <ArticleId IdType="pubmed">32803633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Selivanova LS, Volganova KS, Abrosimov AY. Telomerase reverse transcriptase (TERT) promoter mutations in the tumors of human endocrine organs: Biological and prognostic value. Arkh Patol. 2016;78:62–69. doi: 10.17116/patol201678162-68. In Russian.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.17116/patol201678162-68</ArticleId>
            <ArticleId IdType="pubmed">27077147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekmezci M, Rice T, Molinaro AM, Walsh KM, Decker PA, Hansen H, Sicotte H, Kollmeyer TM, McCoy LS, Sarkar G, et al.  Adult infiltrating gliomas with WHO 2016 integrated diagnosis: Additional prognostic roles of ATRX and TERT. Acta Neuropathol. 2017;133:1001–1016. doi: 10.1007/s00401-017-1690-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-017-1690-1</ArticleId>
            <ArticleId IdType="pmc">PMC5432658</ArticleId>
            <ArticleId IdType="pubmed">28255664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bell RJ, Rube HT, Xavier-Magalhães A, Costa BM, Mancini A, Song JS, Costello JF. Understanding TERT promoter mutations: A common path to immortality. Mol Cancer Res. 2016;14:315–323. doi: 10.1158/1541-7786.MCR-16-0003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-16-0003</ArticleId>
            <ArticleId IdType="pmc">PMC4852159</ArticleId>
            <ArticleId IdType="pubmed">26941407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang JJ, Lin MC, Bai YX, Jing DD, Wong BC, Han SW, Lin J, Xu B, Huang CF, Kung HF. Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res. 2002;62:3226–3232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12036938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng SS, Gao Y, Chau DH, Li GH, Lai LH, Huang PT, Huang CF, Huang JJ, Chen YC, Kung HF, Lin MC. A novel glioblastoma cancer gene therapy using AAV-mediated long-term expression of human TERT C-terminal polypeptide. Cancer Gene Ther. 2007;14:561–572. doi: 10.1038/sj.cgt.7701038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.cgt.7701038</ArticleId>
            <ArticleId IdType="pubmed">17384579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavanya C, Sibin MK, Srinivas Bharath MM, Manoj MJ, Venkataswamy MM, Bhat DI, Narasinga Rao KV, Chetan GK. RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells. Cytotechnology. 2016;68:2311–2321. doi: 10.1007/s10616-016-0025-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10616-016-0025-8</ArticleId>
            <ArticleId IdType="pmc">PMC5101301</ArticleId>
            <ArticleId IdType="pubmed">27757712</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li X, Qian X, Wang B, Xia Y, Zheng Y, Du L, Xu D, Xing D, DePinho RA, Lu Z. Programmable base editing of mutated TERT promoter inhibits brain tumour growth. Nat Cell Biol. 2020;22:282–288. doi: 10.1038/s41556-020-0471-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-020-0471-6</ArticleId>
            <ArticleId IdType="pubmed">32066906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, et al.  Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget. 2012;3:954–987. doi: 10.18632/oncotarget.652.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.652</ArticleId>
            <ArticleId IdType="pmc">PMC3660063</ArticleId>
            <ArticleId IdType="pubmed">23006971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP. Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: Current preclinical and clinical development. Mol Cancer. 2017;16:100. doi: 10.1186/s12943-017-0670-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-017-0670-3</ArticleId>
            <ArticleId IdType="pmc">PMC5463420</ArticleId>
            <ArticleId IdType="pubmed">28592260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA. 2007;104:5569–5574. doi: 10.1073/pnas.0701005104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0701005104</ArticleId>
            <ArticleId IdType="pmc">PMC1838453</ArticleId>
            <ArticleId IdType="pubmed">17376864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Höland K, Boller D, Hagel C, Dolski S, Treszl A, Pardo OE, Cwiek P, Salm F, Leni Z, Shepherd PR, et al.  Targeting class IA PI3K isoforms selectively impairs cell growth, survival, and migration in glioblastoma. PLoS One. 2014;9:e94132. doi: 10.1371/journal.pone.0094132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0094132</ArticleId>
            <ArticleId IdType="pmc">PMC3981776</ArticleId>
            <ArticleId IdType="pubmed">24718026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Mei L, Zhou L, Shen X, Guo C, Zheng Y, Zhu H, Zhu Y, Huang L. PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts. J Neurooncol. 2011;104:155–167. doi: 10.1007/s11060-010-0492-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-010-0492-2</ArticleId>
            <ArticleId IdType="pubmed">21188471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ. Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. Proc Natl Acad Sci USA. 2005;102:1649–1654. doi: 10.1073/pnas.0406789102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0406789102</ArticleId>
            <ArticleId IdType="pmc">PMC545492</ArticleId>
            <ArticleId IdType="pubmed">15668399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baretić D, Williams RL. PIKKs-the solenoid nest where partners and kinases meet. Curr Opin Struct Biol. 2014;29:134–142. doi: 10.1016/j.sbi.2014.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.sbi.2014.11.003</ArticleId>
            <ArticleId IdType="pubmed">25460276</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302. doi: 10.1016/j.cub.2004.06.054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2004.06.054</ArticleId>
            <ArticleId IdType="pubmed">15268862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cornu M, Albert V, Hall MN. mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev. 2013;23:53–62. doi: 10.1016/j.gde.2012.12.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gde.2012.12.005</ArticleId>
            <ArticleId IdType="pubmed">23317514</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawlor MA, Alessi DR. PKB/Akt: A key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114:2903–2910. doi: 10.1242/jcs.114.16.2903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1242/jcs.114.16.2903</ArticleId>
            <ArticleId IdType="pubmed">11686294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, et al.  The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013;19:5722–5732. doi: 10.1158/1078-0432.CCR-13-0527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0527</ArticleId>
            <ArticleId IdType="pmc">PMC3815450</ArticleId>
            <ArticleId IdType="pubmed">24030701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masri J, Bernath A, Martin J, Jo OD, Vartanian R, Funk A, Gera J. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. Cancer Res. 2007;67:11712–11720. doi: 10.1158/0008-5472.CAN-07-2223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-07-2223</ArticleId>
            <ArticleId IdType="pubmed">18089801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agliano A, Balarajah G, Ciobota DM, Sidhu J, Clarke PA, Jones C, Workman P, Leach MO, Al-Saffar NMS. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy. Oncotarget. 2017;8:47969–47983. doi: 10.18632/oncotarget.18206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.18206</ArticleId>
            <ArticleId IdType="pmc">PMC5564619</ArticleId>
            <ArticleId IdType="pubmed">28624789</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chinnaiyan P, Won M, Wen PY, Rojiani AM, Werner-Wasik M, Shih HA, Ashby LS, Michael Yu HH, Stieber VW, Malone SC, et al.  A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblas-toma: Results of NRG Oncology RTOG 0913. Neuro Oncol. 2018;20:666–673. doi: 10.1093/neuonc/nox209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nox209</ArticleId>
            <ArticleId IdType="pmc">PMC5892159</ArticleId>
            <ArticleId IdType="pubmed">29126203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Wen PY, Alfred Yung WK, Berk L, Narasimhan N, Turner CD, Clackson T, Rivera VM, Vogelbaum MA. Ridaforolimus for patients with progressive or recurrent malignant glioma: A perisurgical, sequential, ascending-dose trial. Cancer Chemother Pharmacol. 2012;69:849–860. doi: 10.1007/s00280-011-1773-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00280-011-1773-y</ArticleId>
            <ArticleId IdType="pubmed">22037923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wick W, Gorlia T, Bady P, Platten M, van den Bent MJ, Taphoorn MJ, Steuve J, Brandes AA, Hamou MF, Wick A, et al.  Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082) Clin Cancer Res. 2016;22:4797–4806. doi: 10.1158/1078-0432.CCR-15-3153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-3153</ArticleId>
            <ArticleId IdType="pubmed">27143690</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>U.S National Library of Medincine (NIH)  NCT Neuro Master Match-N2M2 (NOA-20)   ClinicalTrials.gov Identifier: NCT03158389.  https://clinicaltrials.gov/ct2/show/NCT03158389. Accessed May 18, 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>Rodrik-Outmezguine VS, Okaniwa M, Yao Z, Novotny CJ, McWhirter C, Banaji A, Won H, Wong W, Berger M, de Stanchina E, et al.  Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature. 2016;534:272–276. doi: 10.1038/nature17963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature17963</ArticleId>
            <ArticleId IdType="pmc">PMC4902179</ArticleId>
            <ArticleId IdType="pubmed">27279227</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Babak S, Mason WP. mTOR inhibition in glioblastoma: Requiem for a dream? Neuro Oncol. 2018;20:584–585. doi: 10.1093/neuonc/noy034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy034</ArticleId>
            <ArticleId IdType="pmc">PMC5892149</ArticleId>
            <ArticleId IdType="pubmed">29608764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G, et al.  Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:75. doi: 10.1186/s12943-018-0796-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12943-018-0796-y</ArticleId>
            <ArticleId IdType="pmc">PMC5861621</ArticleId>
            <ArticleId IdType="pubmed">29558960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvalho B, Lopes JM, Silva R, Peixoto J, Leitão D, Soares P, Fernandes AC, Linhares P, Vaz R, Lima J. The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. Sci Rep. 2021;11:6067. doi: 10.1038/s41598-021-85385-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-021-85385-1</ArticleId>
            <ArticleId IdType="pmc">PMC7966794</ArticleId>
            <ArticleId IdType="pubmed">33727583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCarty JH. Glioblastoma resistance to anti-VEGF therapy: Has the challenge been MET? Clin Cancer Res. 2013;19:1631–1633. doi: 10.1158/1078-0432.CCR-13-0051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-0051</ArticleId>
            <ArticleId IdType="pmc">PMC3618531</ArticleId>
            <ArticleId IdType="pubmed">23403631</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manneh Kopp RA, Sepúlveda-Sánchez JM, Ruano Y, Toldos O, Pérez Núñez A, Cantero D, Hilario A, Ramos A, de Velasco G, Sánchez-Gómez P, Hernández-Laín A. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab. Clin Transl Oncol. 2019;21:1413–1423. doi: 10.1007/s12094-019-02070-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12094-019-02070-6</ArticleId>
            <ArticleId IdType="pubmed">30877636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, et al.  Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci USA. 2013;110:E2987–E2996. doi: 10.1073/pnas.1302725110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1302725110</ArticleId>
            <ArticleId IdType="pmc">PMC3740879</ArticleId>
            <ArticleId IdType="pubmed">23882082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, et al.  Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: Efficacy, safety, and hepatocyte growth factor and O6-methylguanine-DNA methyltransferase biomarker analyses. J Clin Oncol. 2017;35:343–351. doi: 10.1200/JCO.2015.64.7685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2015.64.7685</ArticleId>
            <ArticleId IdType="pubmed">27918718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia MM, Gil MJ, Losada E, Martin Soberón MC, Mesia Barroso C, Foro P, Capellades J, Sarmiento B, Bruna J, Verger E, et al.  GEINO 1402: A phase Ib dose-escalation study followed by an extension phase to evaluate safety and efficacy of crizotinib in combination with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed glioblastoma (GB. Ann Oncol. 2019;30:v147. doi: 10.1093/annonc/mdz243.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdz243.011</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guillemot F, Zimmer C. From cradle to grave: The multiple roles of fibroblast growth factors in neural development. Neuron. 2011;71:574–588. doi: 10.1016/j.neuron.2011.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neuron.2011.08.002</ArticleId>
            <ArticleId IdType="pubmed">21867876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frinchi M, Bonomo A, Trovato-Salinaro A, Condorelli DF, Fuxe K, Spampinato MG, Mudò G. Fibroblast growth factor-2 and its receptor expression in proliferating precursor cells of the subventricular zone in the adult rat brain. Neurosci Lett. 2008;447:20–25. doi: 10.1016/j.neulet.2008.09.059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neulet.2008.09.059</ArticleId>
            <ArticleId IdType="pubmed">18835325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dienstmann R, Rodon J, Prat A, Perez-Garcia J, Adamo B, Felip E, Cortes J, Iafrate AJ, Nuciforo P, Tabernero J. Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol. 2014;25:552–563. doi: 10.1093/annonc/mdt419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdt419</ArticleId>
            <ArticleId IdType="pmc">PMC4433501</ArticleId>
            <ArticleId IdType="pubmed">24265351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, et al.  COSMIC: Somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777–D783. doi: 10.1093/nar/gkw1121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkw1121</ArticleId>
            <ArticleId IdType="pmc">PMC5210583</ArticleId>
            <ArticleId IdType="pubmed">27899578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatlen MA, Schmidt-Kittler O, Sherwin CA, Rozsahegyi E, Rubin N, Sheets MP, Kim JL, Miduturu C, Bifulco N, Brooijmans N, et al.  Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma. Cancer Discov. 2019;9:1686–1695.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31575540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim RD, Sarker D, Meyer T, Yau T, Macarulla T, Park JW, Choo SP, Hollebecque A, Sung MW, Lim HY, et al.  First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma. Cancer Discov. 2019;9:1696–1707. doi: 10.1158/2159-8290.CD-19-0555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-0555</ArticleId>
            <ArticleId IdType="pubmed">31575541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, Sparidans R, El-Lari M, Wang Y, Lebre MC, Beijnen JH, Schinkel AH. P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554) Int J Pharm. 2020;573:118842. doi: 10.1016/j.ijpharm.2019.118842.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2019.118842</ArticleId>
            <ArticleId IdType="pubmed">31759109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, et al.  Futibatinib is a novel irreversible FGFR 1-4 inhibitor that shows selective antitumor activity against FGFR-deregulated tumors. Cancer Res. 2020;80:4986–4997. doi: 10.1158/0008-5472.CAN-19-2568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-19-2568</ArticleId>
            <ArticleId IdType="pubmed">32973082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, et al.  Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337:1231–1235. doi: 10.1126/science.1220834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1220834</ArticleId>
            <ArticleId IdType="pmc">PMC3677224</ArticleId>
            <ArticleId IdType="pubmed">22837387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andre F, Ranson M, Dean E, Varga A, van der Noll R, Stockman PK, Ghiorghiu D, Kilgour E, Smith PD, Macpherson M, et al.  Abstract LB-145: Results of a phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. Cancer Res. 2013;73:LB–145.</Citation>
        </Reference>
        <Reference>
          <Citation>Takahashi Y, Akahane T, Sawada T, Ikeda H, Tempaku A, Yamauchi S, Nishihara H, Tanaka S, Nitta K, Ide W, et al.  Adult classical glioblastoma with a BRAF V600E mutation. World J Surg Oncol. 2015;13:100. doi: 10.1186/s12957-015-0521-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12957-015-0521-x</ArticleId>
            <ArticleId IdType="pmc">PMC4358908</ArticleId>
            <ArticleId IdType="pubmed">25885250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tosuner Z, Geçer MÖ, Hatiboğlu MA, Abdallah A, Turna S. BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma. Oncol Lett. 2018;16:2402–2408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6036552</ArticleId>
            <ArticleId IdType="pubmed">30013630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raabe EH, Lim KS, Kim JM, Meeker A, Mao XG, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E, et al.  BRAF activation induces transformation and then senescence in human neural stem cells: A pilocytic astrocytoma model. Clin Cancer Res. 2011;17:3590–3599. doi: 10.1158/1078-0432.CCR-10-3349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-10-3349</ArticleId>
            <ArticleId IdType="pmc">PMC4086658</ArticleId>
            <ArticleId IdType="pubmed">21636552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Behling F, Schittenhelm J. Oncogenic BRAF alterations and their role in brain tumors. Cancers (Basel) 2019;11:794. doi: 10.3390/cancers11060794.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11060794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cantwell-Dorris ER, O'Leary JJ, Sheils OM. BRAFV600E: Implications for carcinogenesis and molecular therapy. Mol Cancer Ther. 2011;10:385–394. doi: 10.1158/1535-7163.MCT-10-0799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-10-0799</ArticleId>
            <ArticleId IdType="pubmed">21388974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakajima N, Nobusawa S, Nakata S, Nakada M, Yamazaki T, Matsumura N, Harada K, Matsuda H, Funata N, Nagai S, et al.  BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: A histological and molecular analysis focusing on intratumoral heterogeneity. Brain Pathol. 2018;28:663–673. doi: 10.1111/bpa.12572.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bpa.12572</ArticleId>
            <ArticleId IdType="pmc">PMC8028676</ArticleId>
            <ArticleId IdType="pubmed">29105198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, et al.  Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: Final overall survival results of the randomized BRIM-3 study. Ann Oncol. 2017;28:2581–2587. doi: 10.1093/annonc/mdx339.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/annonc/mdx339</ArticleId>
            <ArticleId IdType="pmc">PMC5834156</ArticleId>
            <ArticleId IdType="pubmed">28961848</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, et al.  Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. Oncol Rep. 2017;38:3291–3296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5783574</ArticleId>
            <ArticleId IdType="pubmed">29039591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Woo PYM, Lam TC, Pu JKS, Li LF, Leung RCY, Ho JMK, Zhung JTF, Wong B, Chan TSK, Loong HHF, Ng HK. Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: A report of two cases. Oncotarget. 2019;10:3818–3826. doi: 10.18632/oncotarget.26932.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.26932</ArticleId>
            <ArticleId IdType="pmc">PMC6557198</ArticleId>
            <ArticleId IdType="pubmed">31217909</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schiff D, Sarkaria J. Dasatinib in recurrent glioblastoma: Failure as a teacher. Neuro Oncol. 2015;17:910–911. doi: 10.1093/neuonc/nov086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov086</ArticleId>
            <ArticleId IdType="pmc">PMC5762007</ArticleId>
            <ArticleId IdType="pubmed">25964312</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, Weber WA. Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and anti-proliferative effects of dasatinib. Cancer Res. 2009;69:3173–3179. doi: 10.1158/0008-5472.CAN-08-3390.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-08-3390</ArticleId>
            <ArticleId IdType="pmc">PMC2749524</ArticleId>
            <ArticleId IdType="pubmed">19318569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galanis E, Anderson SK, Twohy EL, Carrero XW, Dixon JG, Tran DD, Jeyapalan SA, Anderson DM, Kaufmann TJ, Feathers RW, et al.  A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. Cancer. 2019;125:3790–3800. doi: 10.1002/cncr.32340.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.32340</ArticleId>
            <ArticleId IdType="pmc">PMC6788934</ArticleId>
            <ArticleId IdType="pubmed">31290996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava S, Jackson C, Kim T, Choi J, Lim M. A characterization of dendritic cells and their role in immunotherapy in glioblastoma: From preclinical studies to clinical trials. Cancers. 2019;11:537. doi: 10.3390/cancers11040537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11040537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, et al.  A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma. Clin Cancer Res. 2019;25:5799–5807. doi: 10.1158/1078-0432.CCR-19-0261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-19-0261</ArticleId>
            <ArticleId IdType="pmc">PMC8132111</ArticleId>
            <ArticleId IdType="pubmed">31320597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Polson ES, Kuchler VB, Abbosh C, Ross EM, Mathew RK, Beard HA, da Silva B, Holding AN, Ballereau S, Chuntharpursat-Bon E, et al.  KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Sci Transl Med. 2018;10:eaar2718. doi: 10.1126/scitranslmed.aar2718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aar2718</ArticleId>
            <ArticleId IdType="pubmed">30111643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gruslova A, Cavazos DA, Miller JR, Breitbart E, Cohen YC, Bangio L, Yakov N, Soundararajan A, Floyd JR, Brenner AJ. VB-111: A novel anti-vascular therapeutic for glioblastoma multiforme. J Neurooncol. 2015;124:365–372. doi: 10.1007/s11060-015-1853-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-015-1853-7</ArticleId>
            <ArticleId IdType="pmc">PMC4584173</ArticleId>
            <ArticleId IdType="pubmed">26108658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, et al.  Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: Results of a phase I/II study. Neuro Oncol. 2020;22:694–704. doi: 10.1093/neuonc/noz231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noz231</ArticleId>
            <ArticleId IdType="pmc">PMC7229257</ArticleId>
            <ArticleId IdType="pubmed">31844886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomized, double-blind, international phase 3 trial. Lancet Oncol. 2017;18:1373–1385. doi: 10.1016/S1470-2045(17)30517-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(17)30517-X</ArticleId>
            <ArticleId IdType="pubmed">28844499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, et al.  Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): Results of a double-blind randomized phase II trial. Clin Cancer Res. 2020;26:1586–1594. doi: 10.1158/1078-0432.CCR-18-1140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1140</ArticleId>
            <ArticleId IdType="pubmed">32034072</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heimberger AB, Archer GE, Crotty LE, McLendon RE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intrace-rebral melanoma. Neurosurgery. 2002;50:158–166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11844246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: The game is not over yet. Oncotarget. 2017;8:91779–91794. doi: 10.18632/oncotarget.21586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.21586</ArticleId>
            <ArticleId IdType="pmc">PMC5710964</ArticleId>
            <ArticleId IdType="pubmed">29207684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferris RL, Blumenschein G, Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al.  Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–1867. doi: 10.1056/NEJMoa1602252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1602252</ArticleId>
            <ArticleId IdType="pmc">PMC5564292</ArticleId>
            <ArticleId IdType="pubmed">27718784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, et al.  Effect of nivolumab vs bevaci-zumab in patients with recurrent glioblastoma: The CheckMate 143 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1003–1010. doi: 10.1001/jamaoncol.2020.1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2020.1024</ArticleId>
            <ArticleId IdType="pmc">PMC7243167</ArticleId>
            <ArticleId IdType="pubmed">32437507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson JH, Padula Omuro AM, Preusser M, Lim M, Butowski NA, Cloughesy TF, Strauss LC, Latek RR, Paliwal P, Weller M, Reardon DA. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. J Clin Oncol. 2016;34:TPS2079. doi: 10.1200/JCO.2016.34.15_suppl.TPS2079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.34.15_suppl.TPS2079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, De Groot JF, Nghiemphu PL, Kaley TJ, Colman H, Gaffey SC, et al.  Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. J Clin Oncol. 2018;36:2006. doi: 10.1200/JCO.2018.36.15_suppl.2006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.36.15_suppl.2006</ArticleId>
            <ArticleId IdType="pubmed">29763342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate MA, Inogés S, de Andrea C, López-Diaz de Cerio A, Tejada S, et al.  Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nat Med. 2019;25:470–476. doi: 10.1038/s41591-018-0339-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0339-5</ArticleId>
            <ArticleId IdType="pubmed">30742120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al.  Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019;25:477–486. doi: 10.1038/s41591-018-0337-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0337-7</ArticleId>
            <ArticleId IdType="pmc">PMC6408961</ArticleId>
            <ArticleId IdType="pubmed">30742122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Pourpak A, Morris SW. Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem. 2009;52:4981–5004. doi: 10.1021/jm9002395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/jm9002395</ArticleId>
            <ArticleId IdType="pmc">PMC2888655</ArticleId>
            <ArticleId IdType="pubmed">19610618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res. 2002;62:200–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11782378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou X, Shen F, Ma P, Hui H, Pei S, Chen M, Wang Z, Zhou W, Jin B. GSK1838705A, an IGF-1R inhibitor, inhibits glioma cell proliferation and suppresses tumor growth in vivo. Mol Med Rep. 2015;12:5641–5646. doi: 10.3892/mmr.2015.4129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3892/mmr.2015.4129</ArticleId>
            <ArticleId IdType="pmc">PMC4581800</ArticleId>
            <ArticleId IdType="pubmed">26238593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osher E, Macaulay VM. Therapeutic targeting of the IGF axis. Cells. 2019;8:895. doi: 10.3390/cells8080895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8080895</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Janes PW, Vail ME, Gan HK, Scott AM. Antibody targeting of eph receptors in cancer. Pharmaceuticals. 2020;13:88. doi: 10.3390/ph13050088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/ph13050088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderton M, van der Meulen E, Blumenthal MJ, Schäfer G. The role of the Eph receptor family in tumorigenesis. Cancers (Basel) 2021;13:206. doi: 10.3390/cancers13020206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13020206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, et al.  The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell. 2012;22:765–780. doi: 10.1016/j.ccr.2012.11.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2012.11.005</ArticleId>
            <ArticleId IdType="pmc">PMC3922047</ArticleId>
            <ArticleId IdType="pubmed">23238013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005;3:541–551. doi: 10.1158/1541-7786.MCR-05-0056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1541-7786.MCR-05-0056</ArticleId>
            <ArticleId IdType="pubmed">16254188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, et al.  KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res. 2016;50:123–131. doi: 10.1016/j.leukres.2016.09.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.leukres.2016.09.012</ArticleId>
            <ArticleId IdType="pubmed">27736729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83–96. doi: 10.1038/nrc3430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3430</ArticleId>
            <ArticleId IdType="pmc">PMC4161369</ArticleId>
            <ArticleId IdType="pubmed">23303139</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Avci NG, Ebrahimzadeh-Pustchi S, Akay YM, Esquenazi Y, Tandon N, Zhu JJ, Akay M. NF-κB inhibitor with Temozolomide results in significant apoptosis in glioblastoma via the NF-κB(p65) and actin cytoskeleton regulatory pathways. Sci Rep. 2020;10:13352. doi: 10.1038/s41598-020-70392-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-020-70392-5</ArticleId>
            <ArticleId IdType="pmc">PMC7414229</ArticleId>
            <ArticleId IdType="pubmed">32770097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beck S, Jin X, Sohn YW, Kim JK, Kim SH, Yin J, Pian X, Kim SC, Nam DH, Choi YJ, Kim H. Telomerase activity-independent function of TERT allows glioma cells to attain cancer stem cell characteristics by inducing EGFR expression. Mol Cells. 2011;31:9–15. doi: 10.1007/s10059-011-0008-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10059-011-0008-8</ArticleId>
            <ArticleId IdType="pmc">PMC3906874</ArticleId>
            <ArticleId IdType="pubmed">21193962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Olympios N, Gilard V, Marguet F, Clatot F, Di Fiore F, Fontanilles M. TERT promoter alterations in glioblastoma: A systematic review. Cancers (Basel) 2021;13:1147. doi: 10.3390/cancers13051147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13051147</ArticleId>
            <ArticleId IdType="pmc">PMC7962450</ArticleId>
            <ArticleId IdType="pubmed">33800183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Metro G, Pierini T, La Starza R.  TERT Mutations in Glioma: ESMO Biomarker Factsheet. European Society for Medical Oncology; Lugano: 2019.   https://oncologypro.esmo.org/education-library/factsheets-on-biomarkers/tert-mutations-in-glioma. Accessed January 25, 2019.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
